# SYSTEMATIC REVIEW

# Periodontal Parameters in Fixed Labial and Lingual Orthodontic Treatment: A Systematic Review and Meta-Analysis

Mingrui Zhai <sup>a</sup> / Mengqiao Wang<sup>b</sup> / Lan Li <sup>c</sup> / Bohui Liu<sup>d</sup> / Fulan Wei<sup>e</sup>

Purpose: To critically evaluate the periodontal parameters of patients receiving fixed labial and lingual orthodontic therapy.

**Materials and Methods:** The current systematic review was registered at PROSPERO. Clinical studies comparing the periodontal parameters between fixed labial and lingual orthodontic treatment were searched up to June 2022 in four electronic databases, and unpublished literature was searched at ClinicalTrial.gov. The risk of bias of randomised controlled clinical trials (RCTs) and non-randomised clinical trials (n-RCTs) was assessed using the Cochrane risk-of-bias tool 2.0 and the Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) assessment tool, respectively. The pooled periodontal parameters were calculated in random-effect meta-analyses. The confidence of evidence was assessed via the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.

**Results:** Eight studies involving 223 patients were included in the current study. The risk of bias was high for 2 RCTs and 3 n-RCTs, and moderate for 3 n-RCTs. Patients receiving fixed lingual orthodontic treatment showed a lower plaque index (MD = -0.14; 95%CI -0.27 to -0.02). No statistically significant difference was found in the bleeding on probing index (MD = 0.11; 95%CI -0.03 to 0.25), gingival index (MD = 0.02; 95%CI -0.06 to 0.11), and periodontal pocket depth (MD = 0.06; 95%CI -0.16 to 0.27) between the two groups. The overall quality of the evidence was very low to low.

**Conclusion:** The present study indicates no obvious difference in periodontal parameters between the fixed labial and lingual orthodontic systems, although the overall quality was very low to low. Further RCTs with standardised outcome measures are needed.

Key words: meta-analysis, periodontal health, orthodontics, systematic review

Oral Health Prev Dent 2022; 20: 475-484. doi: 10.3290/j.ohpd.b3601703 Submitted for publication: 06.09.22; accepted for publication: 04.11.22

Orthodontic treatment aims to provide an acceptable functional and aesthetic occlusion. Fixed orthodontic appliances have become an integral part of modern orthodontics and are extensively used in clinics.<sup>17</sup> However, fixed orthodontic appliances have been reported to be associated with impaired oral hygiene because of the increased niches for plaque retention and biofilm formation, as well as the

<sup>a</sup> Postgraduate Student, Department of Orthodontics, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, Jinan, China; Shandong Key Laboratory of Oral Tissue Regeneration, Jinan, China; Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, Jinan, China. Study concept, design and planning, collected data, wrote the manuscript, read and approved the final manuscript.

<sup>b</sup> Postgraduate Student, Department of Orthodontics, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, Jinan, China; Shandong Key Laboratory of Oral Tissue Regeneration, Jinan, China; Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, Jinan, China. Study concept, design and planning, collected data, read and approved the final manuscript.

<sup>c</sup> Postgraduate Student, Department of Orthodontics, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, Jinan, China; Shandong Key Laboratory of Oral Tissue Regeneration, Jinan, China; Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, Jinan, China. Study concept, design and planning, collected data, read and approved the final manuscript. increased difficulty in removing plaque mechanically.<sup>29,42</sup> It has been reported that once the homeostatic balance between subgingival microbial communities and adjacent host tissue has been disturbed, the accumulated subgingival biofilms would initiate the development of gingivitis.<sup>6,16,18</sup> Furthermore, gingivitis can further progress to periodontitis, which may result in long-term, irreversible damage to peri-

- <sup>d</sup> Postgraduate Student, Department of Orthodontics, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, Jinan, China; Shandong Key Laboratory of Oral Tissue Regeneration, Jinan, China; Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, Jinan, China. Study concept, design and planning, read and approved the final manuscript.
- <sup>e</sup> Professor, Department of Orthodontics, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, Jinan, China; Shandong Key Laboratory of Oral Tissue Regeneration, Jinan, China; Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, Jinan, China. Study concept, design and planning, collected and analysed data, wrote the manuscript, read and approved the final manuscript, project administration.

**Correspondence:** Fulan Wei, Department of Orthodontics, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, No.44-1 Wenhua Road West, 250012, Jinan, Shandong, China. Tel: +86-139-6916-9965; e-mail: weifl@sdu.edu.cn

Database	Search methods
Web of Science	<pre>#1 TS= (buccal OR labial OR vestibular) OR TS= (lingual) #2 TS= (bracket* OR orthodontic) #3 TS= (vivo OR clinical) #4 TS= (vitro) #5 TS= (periodontal OR gingival OR bleed* OR adverse) #1 AND #2 AND #3 AND #5 NOT #4</pre>
Pubmed	(("buccal"[All Fields] OR "buccally"[All Fields] OR ("labially"[All Fields] OR "lip"[MeSH Terms] OR "lip"[All Fields] OR "labials"[All Fields]) OR "vestibular"[All Fields] OR ("lingualized"[All Fields] OR "lingually"[All Fields] OR "tongue"[MeSH Terms] OR "tongue"[All Fields]) OR "vestibular"[All Fields] OR ("lingualized"[All Fields] OR "lingually"[All Fields] OR "tongue"[MeSH Terms] OR "tongue"[All Fields] OR ("orthodontal"[All Fields]) AND ("bracket"[All Fields] OR "bracket s"[All Fields] OR "orthodontics"[All Fields] OR "trials"[All Fields] OR "periodontics"[All Fields] OR "gingiva"[All Fields] OR "gingiva"[All Fields] OR "gingiva"[All Fields] OR "gingivals"[All Fields] OR "gingivitis"[All Fields] OR "gi
Scopus	(TITLE-ABS-KEY (buccal OR labial OR vestibular) OR TITLE-ABS-KEY (lingual) AND TITLE-ABS-KEY (bracket OR orthodontic) AND TITLE-ABS-KEY (vivo OR clincial) AND NOT TITLE-ABS-KEY (vitro) AND TITLE-ABS-KEY (periodontal OR gingival OR bleed OR adverse))
Embase	"(buccal OR labial OR vestibular) OR (lingual) AND (periodontal OR gingival OR bleed OR adverse) AND (vivo OR clincial) NOT (vitro)"
Clinicaltrial.gov	periodontal   orthodontic   fixed buccal and lingual orthodontic bracket

#### **Table 1** Search strategies applied in the current study

odontal tissues.<sup>5,30</sup> Therefore, it is of critical importance to monitor the alterations in clinical periodontal parameters after fixed orthodontic appliance insertion.

Traditional fixed orthodontic appliances were fixed on the labial surface of the teeth. Recently, the fixed lingual orthodontic appliance was invented and developed, and has since become an alternative to conventional labial orthodontic appliances due to its excellent aesthetics and growing practicability.<sup>8,27</sup> Numerous investigations have been conducted to compare traditional labial orthodontic treatment and novel lingual orthodontic treatment.<sup>1,22,27,42</sup> Evidence has confirmed that satisfying treatment outcomes could both be achieved by using either of the two orthodontic appliances.<sup>23</sup> When taking clinical periodontal parameters into account, the standpoints on comparison between the two fixed orthodontic systems have been controversial. Some found deteriorated oral hygiene and periodontal parameters during fixed lingual orthodontic treatment compared to traditional labial orthodontic therapy.<sup>21,40,43</sup> In contrast, others reported a lower risk of caries in the fixed lingual orthodontic treatment. However, to our knowledge, the investigations concerning clinical periodontal parameters have never been pooled in a systematic way.

Several systematic reviews have made great efforts to compare oral hygiene between fixed labial and lingual orthodontic treatment, 1, 22, 27 revealing greater difficulty in taking oral hygiene measures with fixed lingual brackets. However, these reviews only focused on oral hygiene and the difficult access during hygiene measures, instead of clinical periodontal parameters, which were more objective and were appraised by professional periodontists. The two available reviews regarding oral hygiene and the difficulty of performing hygiene measures were conducted almost six years ago.1,27 Since then, many primary studies have been published.<sup>3,10,40,41,43</sup> No comprehensive approach has been followed to date to review the existing evidence on clinical periodontal parameters. Therefore, the aim of the present systematic review was to assess the current literature in terms of the comparison of periodontal parameters between patients receiving fixed labial and lingual orthodontic treatment.

# **MATERIALS AND METHODS**

This meta-analysis was conducted and reported according to the Cochrane Handbook for Systematic Reviews of Interventions, version 6.2, and the 2020 checklist for the Pre-




Fig 1 PRISMA flow diagram of the search processes and results.

ferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA).<sup>12,26</sup> The protocol for this systematic review and meta-analysis was registered with the International Prospective Register of Systematic Reviews (PROS-PERO) (https://www.crd.york.ac.uk/PROSPERO/) under registration number CRD42020188538.

# **Eligibility Criteria**

According to the "participants, intervention, comparison, outcome, and study design (PICOS)" principle, the current study was designed to compare the clinical periodontal parameters between patients receiving fixed labial and lingual orthodontic treatment. The inclusion and exclusion criteria for study selection were:

- Patients: all patients treated with fixed labial and all patients treated with lingual orthodontic appliances were included; patients with systemic diseases, cleft lip, cleft palate, or other craniofacial abnormalities were excluded.
- Interventions: studies using fixed labial and lingual orthodontic appliances were included; additional treatments such as maxillofacial surgery were excluded.
- Comparison: fixed labial orthodontic treatment vs fixed lingual orthodontic treatment; excluded if there was no comparison between fixed labial and lingual orthodontic treatment.

- Outcome: all clinical periodontal parameters were included; outcomes not relevant to periodontal status were excluded.
- Study design: randomised controlled clinical trials and non-randomised clinical trials were included; systematic reviews, case reports, in-vitro studies, or animal studies were excluded.

#### **Information Sources and Literature Search**

The following four electronic databases were searched up to June 2022 without any limits: Web of Science, Embase, Pubmed, and Scopus. In addition, studies from the grey literature were searched in ClinicalTrial.gov. Hand searching was conducted in the retrieved literature for any additional articles that were eligible for the current systematic review. The search strategies applied are detailed in Table 1.

#### **Study Selection**

All the studies retrieved from the search procedures were imported into Endnote software to discard duplicates. Two independent reviewers evaluated the eligibility of each study according to the pre-established inclusion and exclusion criteria. Briefly, the titles and abstracts of the studies were independently screened by two reviewers. The full text of the studies was obtained and assessed for fulfilling the

#### Table 2 Summary of characteristics of studies included in the systematic review

Author and year	Study Design	Sample Size	Age	Gender	Outcomes	Timepoints of measurements
Vijaykumar et al, 2020	Non-randomised clinical trial (two-arm, parallel)	Labial: N = 10 Lingual: N = 10	NR	NR	PI CI GI	T1: one month T2: three months
Zhang et al, 2018	Non-randomised clinical trial (Two-arm parallel)	Labial: N = 15 Lingual: N = 15	NR	Labial: M/F = 6:9 Lingual: M/F = 8:7	PPD GI BOP	T0: before treatment T1: three months T2: six months
Lombardo et al, 2013	Non-randomised clinical trial (Two-arm parallel)	Labial: N = 10 Lingual: N = 10	Labial: 19.3 ± 3.6 Lingual: 22.3 ± 3.2	Labial: M/F = 2:8 Lingual: M/F = 3:7	PI BOP Salivary flow rate Salivary pH Streptococcus mutans counts Lactobacillus counts	T0: before placement T1: 4 weeks T2: 8 weeks
Sfondrini et al, 2012	Randomised controlled trial (split-mouth)	Labial: N = 20 Lingual: N = 20	Labial: 23.8 ± 2.4 Lingual: 23.8 ± 2.4	Labial: M/F = 6:14 Lingual: M/F = 6:14	PPD BOP Streptococci count Anaerobe count Total count	T0: 1 day T1: 7 days T2: 30 days
Bruno et al, 2019	Randomised controlled trial (Two-arm parallel)	Labial: N = 10 Lingual: N = 10	NR	Labial: M/F = 2:8 Lingual: M/F = 1:9	PI GI	T0: before bonding T1: one month T2: three months T3: six months
Tapia-Rivea et al, 2015	Non-randomised clinical trial (Two-arm parallel)	Labial: N = 40 Lingual: N = 43	SP Labial: 19.6 ± 8.9 Lingual: 34 ± 12.1 MS Labial: 28.8 ± 14.2 Lingual: 29.2 ± 10.5	SP Labial: NR Lingual: M/F = 40% MS Labial: NR Lingual: M/F = 29%	VP BOP OHI-S MGI	At three months after bonding brackets
Wang et al, 2018	Non-randomised clinical trial (Two-arm parallel)	Labial: N = 16 Lingual: N = 14	NR	NR	GI PI PPD SBI	T0: before bracket placement T1: one month T2: three months T3: six months T4: one month after treatment

N: number; SP: São Paulo clinic; MS: Mato Grosso do Sul clinic. M/F: the ratio of male and female; NR: not reported; RCT: randomised controlled trial; CCT: controlled clinical trial; Labial: fixed labial orthodontic treatment group; lingual: fixed lingual orthodontic treatment group; PI: plaque index; CI: calculus index; GI: gingival index; PPD: periodontal pocket depth; BOP: bleeding on probing index; MGI: modified gingival index; OH-S: oral hygiene index; VP: visible plaque; SBI: sulcus bleeding index.

inclusion criteria after screening the titles and abstracts. When necessary, corresponding authors were contacted for further information. Any disagreements concerning the eligibility were resolved by consensus; otherwise, the opinion of the third reviewer was referred to.

#### **Risk of Bias Assessment**

The assessment of the risk of bias in randomised controlled clinical trials (RCTs) and non-randomised clinical trials (n-RCTs) was conducted according to the Revised Cochrane risk-of-bias tool 2.0 for randomised trials<sup>35</sup> and the Risk Of Bias In Non-randomised Studies of Interventions (ROBINS-I) assessment tool.<sup>34</sup>

# **Data Extraction**

A pre-established data extraction table was used for information extraction; this procedure was also conducted by two independent reviewers. Missing data were acquired from the corresponding author of the pertinent literature; otherwise, only the available data was included.

#### **Data Analysis**

Methodological and clinical heterogeneity were evaluated by examining the study characteristics, similarity of participant characteristics, interventions, and study outcomes, as specified in the inclusion and exclusion criteria for the present systematic review. The I<sup>2</sup> and X<sup>2</sup> tests were used to determine statistical heterogeneity.13 Meta-analysis was performed using Review Manager 5 (version 5.3; Nordic Cochrane Centre, Cochrane Collaboration; Copenhagen, Denmark). Mean differences (MD) and standard deviations (SD) were used to summarise the data from each study. Pooled estimates and 95% confidence intervals (CI) were presented if two or more studies reporting consistent periodontal indices were deemed eligible for a single comparison. Further, a random-effects model was applied in the current meta-analysis.<sup>33</sup> Forest plots were made to graphically explain the meta-analysis results, in which the effect size of each outcome and the heterogeneity were presented. Subgroup analyses based on follow-up periods were pre-determined to explore the effect of the follow-up time on pooled results. Sensitivity analyses Table 3 Risk of bias assessment according to Cochrane risk-of-bias tool 2.0

Study	Sfondrini et al, 2012	Bruno et al, 2019
Risk of bias arising from the randomisation process	Low	Low
Risk of bias due to deviations from the intended interventions	High	High
Missing outcome data	Low	Low
Risk of bias in measurement of the outcome	Some concerns	High
Risk of bias in selection of the reported result	Low	Low
Overall risk of bias	High	High

 Table 4
 Risk-of-bias assessment of non-randomised clinical trials using ROBINS-I tool

Domains	Vijaykumar et al, 2020	Zhang et al, 2018	Lombardo et al, 2013	Tapia-Rivera et al, 2015	Wang et al, 2018	Gujar et al, 2020
Bias due to confounding	Low	Low	Low	Serious	Low	Serious
Bias in selection of participants into the study	Serious	Low	Moderate	Serious	Moderate	Low
Bias in classification of interventions	Low	Low	Low	Low	Low	Low
Bias due to deviations from intended interventions	Low	Moderate	Low	Moderate	Low	Low
Bias due to missing data	Low	Low	Low	Serious	Low	Serious
Bias in measurement of outcomes	Low	Moderate	Low	Moderate	Low	Moderate
Bias in selection of reported results	Low	Low	Low	Low	Low	Low
Overall bias	Serious	Moderate	Moderate	Serious	Moderate	Serious

were also conducted, if applicable. The formal testing for publication bias was evaluated using funnel plots and the Egger test, if there were at least ten studies involved.<sup>19</sup>

# **Quality Assessment of the Outcome**

The overall quality of evidence was evaluated through the GRADE approach using GRADE profile version 3.6 software.<sup>11</sup> When assessing the overall quality, the risk of bias of each outcome in each study was evaluated again, so that the risk of bias was assessed at the outcome level.

# RESULTS

The data that support the findings of this study are available from the corresponding author upon reasonable request.

# **Characteristics of Included Studies**

The study flowchart is shown in Fig 1. A total of 616 papers were initially retrieved, and 308 studies were left after removing duplicates. Finally, 8 studies comprising 223 patients<sup>3,10,21,31,36,40,41,43</sup> were considered eligible for the present systematic review, and 5 studies<sup>3,31,40,41,43</sup> were appropriate for quantitative analyses. In terms of including and excluding studies, there was substantial agreement between the two reviewers (K = 0.973).<sup>4</sup>

Two of the included studies were RCTs<sup>3,31</sup> and six were n-RCTs.  $^{10,21,36,40,41,43}$  Seven studies  $^{3,10,21,36,40,41,43}$  were based on a parallel two-arm design, and one study<sup>31</sup> was based on a split-mouth design. The sample size of included studies ranged from 20 to 83 participants with age varying from 19 to 34 years. Balanced recruitment of participants of similar age was present in the majority of studies included in the current review. However, whether or not the distribution of gender was similar between the two groups could not be verified due to missing data in several investigations.<sup>40,41</sup> The main reported clinical periodontal outcomes focused on four clinical periodontal parameters: plaque index (PI), gingival index (GI), bleeding on probing index (BOP), and periodontal pocket depth (PPD). The follow-up duration ranged from one week after the start of orthodontic treatment to one month after completing orthodontic treatment. Other basic data and information could be found in Table 2.

# **Risk of Bias of Included Studies**

Two included RCTs<sup>3,31</sup> were both evaluated as high risk of bias using the ROB2.0 assessment tool (Table 3). Considering randomisation, Sfondrini et al<sup>31</sup> performed randomisation by means of concealed envelopes, and Bruno et al<sup>3</sup> used a random numbers table of the groups. The high risk of bias mainly pertained to deviations from the intended

Study or Subarous	labial Mean SD	Total M	lingual lean SD	Total		Mean Difference IV. Random, 95% CI	Mean Difference IV, Random, 95% Cl		Mean Difference /. Random, 95% Cl
1.1.1 Pl in the first		Lotal In	San Ob	1 State	cosigna.	CC. I SHI MANDA SALE AN		1.2.1 BOP in the first month	Third State Providence
Bruno2019	0.62 0.32		0.57 0.36		12.2%	0.05 [-0.25, 0.35]		wang2018 1.38 0.23 16 1.38 0.23 14 20.2% 0.00 [-0.16, 0.16]	-
Vijaykumar2020	1 0.8		1 0.7		3.3%	0.00 [-0.66, 0.66]		Subtotal (95% CI) 16 14 20.2% 0.00 [-0.16, 0.16]	-
wang2018 Subtotal (95% CI)	1.57 0.21	16	1.22 0.44		15.2%	0.35 [0.10, 0.60] 0.19 [-0.04, 0.42]		Heterogeneity: Not applicable	
Heterogeneity: Tau	= 0.01 Chi = 26		(P = 0.26)			0.13 [-0.04, 0.42]	-	Test for overall effect: Z = 0.00 (P = 1.00)	
Test for overall effer			h - owny					1.2.2 BOP in the third month	
								wang2018 1.27 0.25 16 1.47 0.31 14 17.7% -0.20 [-0.40, 0.00]	-
1.1.3 PI in the third Bruno2019				1.22				zhang2018 2.18 0.18 15 2.53 0.24 15 21.1% -0.35 [-0.50, -0.20] Subtotal (95% Cl) 31 29 38.8% -0.29 [-0.43, -0.15]	
Bruno2019 Všavkumar2020	0.67 0.41				2.3%	0.02 [-0.27, 0.31]		Subtotal (95% Cl) 31 29 38.8% -0.29 [-0.43, -0.15] Heterogeneity: Tau <sup>2</sup> = 0.00: Chi <sup>2</sup> = 1.34, df = 1 (P = 0.25); I <sup>2</sup> = 25%	
wang2018	1.57 0.16		1.35 0.34		20.3%	0.22 [0.03, 0.41]		Test for overall effect: Z = 3.97 (P < 0.0001)	
Subtotal (95% CI)		36		34	35.4%	0.02 [-0.31, 0.35]	-		
Heterogeneity: Tau			(P = 0.06);	P = 645				1.2.3 BOP in the sixth month	
Test for overall effe	ct: Z = 0.11 (P = 0.	91)						wang2018 1.23 0.33 16 1.17 0.37 14 14.9% 0.06 [-0.19, 0.31]	
1.1.4 PI in the sixt!	month							zhang2018 2.94 0.32 15 3.03 0.12 15 19.7% -0.09 [-0.26, 0.08] Subtotal (95% CI) 31 29 34.6% -0.04 [-0.18, 0.10]	-
Bruno2019	0.74 0.32	10	0.7 0.24	10	15.5%	0.04 [-0.21, 0.29]		Heterogeneity: Tau <sup>a</sup> = 0.00: Chi <sup>a</sup> = 0.92, df = 1 (P = 0.34); I <sup>a</sup> = 0%	
wang2018	1.45 0.13	16	1.1 0.58	14	11.5%	0.35 [0.04, 0.66]		Test for overall effect: Z = 0.58 (P = 0.56)	
Subtotal (95% CI)	7.11.2.2.2.2.2.2.2	26			27.0%	0.18 [-0.12, 0.48]			
Heterogeneity: Tau Test for overall effer			(P = 0.13);	r = 579	5			1.2.4 BOP at one month after orthodontic treatment wang2018 1.77 0.65 16 1.65 0.73 14 6.4% 0.12 [-0.38, 0.62]	
reation overall end	1.11 (P = 0.							Subtotal (95% CI) 16 1.65 0.73 14 6.4% 0.12 [-0.36, 0.62]	
1.1.5 Pl at one mor								Heterogeneity: Not applicable	
wang2018 Subtotal (95% CI)	1.62 0.33	16 16	1.56 0.76		7.0%	0.06 [-0.37, 0.49] 0.06 [-0.37, 0.49]		Test for overall effect: Z = 0.47 (P = 0.64)	
Subtotal (95% CI) Heterogeneity: Not	annlicable	10		14	1.076	e.de [-0.57, 0.43]		Total (95% Cl) 94 86 100.0% -0.11 [-0.25, 0.03]	+
Test for overall effer		78)						Heterogeneity: Taul = 0.02; Chil = 14.23; df = 5 /P = 0.01; il = 65%	
								Test for overall effect: Z = 1.51 (P = 0.13)	0.25 0 0.25 0.5 [labial] Favours [lingual]
Total (95% CI)		114			100.0%	0.14 [0.02, 0.27]	•	Test for subaroup differences: Chi <sup>2</sup> = 9.48. df = 3 (P = 0.02), I <sup>2</sup> = 68.4%	formed . moons furtheast
Heterogeneity: Tau Test for overall effe			8 (P = 0.19)	14 = 29	76	7	1 -0.5 0 0.5 1		
Test for subgroup d			3 (P = 0.82	). P=0	s		Favours [labial] Favours [lingual]		
		Total M	lingual lean SD	Total	Weight	Mean Difference IV. Random. 95% Cl	Mean Difference IV. Random, 95% Cl	Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% CI IV	Mean Difference 7. Random, 95% Cl
1.3.1 GI in the first Bruno2019	month 0.12 0.2	10	0.18 0.16	10	14.2%	IV. Random. 95% CI			
1.3.1 GI in the first Bruno2019 Vijaykumar2020	Mean SD month 0.12 0.2 1.3 0.8	10 10	lean SD 0.18 0.16 0.8 0.6	10 10	14.2%	IV. Random. 95% CI -0.06 [-0.22, 0.10] 0.50 [-0.12, 1.12]		Study or Subgroup.         Mean         SD.         Total         Weight         IV. Random. 95%. CI         IV           1.41.9PD in the first week         storogin2012         1.35         0.46         20         1.27.%         0.11 [-0.16, 0.40]           Subtrate (INFS) CT)         20         1.27.%         0.11 [-0.16, 0.40]         20         1.27.%         0.11 [-0.16, 0.40]	
1.3.1 GI in the first Brunc2019 Vijaykumar2020 wang2018	month 0.12 0.2	10 10 16	0.18 0.16	10 10 14	14.2% 1.6% 8.3%	IV. Random. 95% Cl -0.06 [-0.22, 0.10] 0.50 [-0.12, 1.12] 0.05 [-0.19, 0.29]		Study of Subgroup         Mean         SD         Total         Weight         IV. Random. 95%; CI         IV           1.4.1 PPD in the first week schorthra012         1.35         0.46         20         1.27%         0.11 [-0.18, 0.40]           Subdeal (95%; CI)         20         29         12.7%         0.11 [-0.18, 0.40]           Budbeal (95%; CI)         20         29         12.7%         0.11 [-0.18, 0.40]	
1.3.1 GI in the first Brunc2019 Vijaykumar2020 wang2018 Subtotal (95% CI)	month 0.12 0.2 1.3 0.8 1.18 0.26	10 10 16 36	lean SD 0.18 0.16 0.8 0.6 1.13 0.39	10 10 14 34	14.2% 1.6% 8.3% 24.0%	IV. Random. 95% CI -0.06 [-0.22, 0.10] 0.50 [-0.12, 1.12]		Study or Subgroup.         Mean         SD.         Total         Weight         IV. Random. 95%. CI         IV           1.41.9PD in the first week         storogin2012         1.35         0.46         20         1.27.%         0.11 [-0.16, 0.40]           Subtrate (INFS) CT)         20         1.27.%         0.11 [-0.16, 0.40]         20         1.27.%         0.11 [-0.16, 0.40]	
1.3.1 GI in the first Brunc2019 Vijaykumar2020 wang2018	Mean SD month 0.12 0.2 1.3 0.8 1.18 0.26 = 0.01; Chi <sup>2</sup> = 3.2	10 10 16 36 1. df = 2	lean SD 0.18 0.16 0.8 0.6 1.13 0.39	10 10 14 34	14.2% 1.6% 8.3% 24.0%	IV. Random. 95% Cl -0.06 [-0.22, 0.10] 0.50 [-0.12, 1.12] 0.05 [-0.19, 0.29]		Bindy cof Subgroup         Mean         SD         Total         Weight         IV. Random, 95%, CI         IV           14.1 PPD in the first week         infondroi/12         1.35         0.46         20         12.7%         0.11 [-0.16, 0.40]           Substatel (95% CI)         20         20         12.7%         0.11 [-0.16, 0.40]           Hetrogenetity: Not applicable         20         20         12.7%         0.11 [-0.16, 0.40]           Hetrogenetity: Not applicable         20         20         12.7%         0.11 [-0.16, 0.40]           14.2 PPD in the first month         14.2 PPD in the first month         14.2         14.2         14.2	
1.3.1 GI in the first Brunc2019 Vijaykumar2020 wang2018 Subtotal (95% CI) Heterogeneity: Tau' Test for overall effer	Mean         SD           month         0.12         0.2           1.3         0.8         1.18         0.26           r = 0.01; Chi² = 3.2         ct; Z = 0.30 (P = 0.25)         0.26	10 10 16 36 1. df = 2	lean SD 0.18 0.16 0.8 0.6 1.13 0.39	10 10 14 34	14.2% 1.6% 8.3% 24.0%	IV. Random. 95% Cl -0.06 [-0.22, 0.10] 0.50 [-0.12, 1.12] 0.05 [-0.19, 0.29]		Bindly of Subgroup         Mean         SD         Total         Weight         N. Random. SD. Cf         IV           14.1 PPD in the first week         stondsrai(95% Cf)         20         24         0.49         20         12.7%         0.11 [-0.18, 0.40]           Substoal (95% Cf)         20         24         0.49         20         12.7%         0.11 [-0.18, 0.40]           Heinzogeneity, Not applicatio         20         2.9         2.7%         0.11 [-0.18, 0.40]           Heinzogeneity, Not applicatio         20         2.9         2.9%         0.11 [-0.18, 0.40]           Test to constal factor, 2.4         0.6         1.4         2.0         1.49         1.40           Heinzogeneity, Not applicatio         2.0         2.9%         0.05 [-0.32, 0.22]         1.43         0.45         20         1.32%         -0.05 [-0.32, 0.22]         1.32%         -0.05 [-0.32, 0.22]         1.33         0.41         20         1.43         0.45         20         1.32%         -0.05 [-0.32, 0.22]         1.43         0.45         20         1.32%         -0.05 [-0.32, 0.22]         1.43         1.45         1.45         1.45         1.45         1.45         1.45         1.45         1.45         1.45         1.45         1.45         1.4	
1.3.1 GI in the first Brunc2019 Vijaykumar2020 wang2018 Subtotal (95% CI) Heterogeneity: Tau Test for overall effer 1.3.2 GI in the third	Mean         SD           month         0.12         0.2           1.3         0.8         1.18         0.26           r = 0.01; Chi² = 3.2         ct; Z = 0.30 (P = 0.31)         0.26           d month         0.21         0.21         0.21         0.21	10 10 16 36 1, df = 2 77)	lean SD 0.18 0.16 0.8 0.6 1.13 0.39 (P = 0.20);	10 10 14 34 P = 38%	14.2% 1.6% 8.3% 24.0%	IV, Random, 95% Cl -0.06 [-0.22, 0.10] 0.50 [-0.12, 1.12] 0.05 [-0.19, 0.29] 0.03 [-0.16, 0.22]		Bindy cof Subgroup         Mean         SD         Total         Weight         IV. Random. 35%, CI         IV           14.1 PPD in the first week         infondroot         13.3         0.46         20         12.7%         0.11 [-0.16, 0.40]           Substati (BYS, CI)         20         20         12.7%         0.11 [-0.16, 0.40]           Hetrogenetity: Not applicable         20         12.7%         0.11 [-0.16, 0.40]           Hetrogenetity: Not applicable         70.46)         70.46         70.46)           14.2 PPD in the first month         90.46         14.3         0.45         20         13.2%         -0.05 [-0.32, 0.22]           wwsp2016         2.44         0.4         16         16         14         14.2%         -0.20 [0.06, 0.50]	
1.3.1 GI in the first Brunc2019 Vijaykumar2020 wang2018 Subtotal (95% CI) Heterogeneity: Tau' Test for overall effer	Mean         SD           month         0.12         0.2           1.3         0.8         1.18         0.26           r = 0.01; Chi² = 3.2         ct; Z = 0.30 (P = 0.25)         0.26	10 10 16 36 1, df = 2 77)	lean SD 0.18 0.16 0.8 0.6 1.13 0.39	10 10 14 34 F = 38%	14.2% 1.6% 8.3% 24.0%	IV. Random. 95% Cl -0.06 [-0.22, 0.10] 0.50 [-0.12, 1.12] 0.05 [-0.19, 0.29]		Bindly of Subgroup         Mean         SD         Total         Weight         N. Random. SD. Cf.         IV           14.1 PPD in the first week         stondsrai(95% Cf)         20         24         0.49         20         12.7%         0.11 [-0.18, 0.40]           Substoal (95% Cf)         20         24         0.49         20         12.7%         0.11 [-0.18, 0.40]           Heinzogeneity, Not applicatio         20         2.9         2.7%         0.11 [-0.18, 0.40]           Heinzogeneity, Not applicatio         20         2.9         2.9%         0.11 [-0.18, 0.40]           Heinzogeneity, Not applicatio         2.0         2.9%         0.01 [-0.18, 0.40]         1.40           Heinzogeneity, Not application         2.0         2.9%         0.01 [-0.18, 0.40]         1.40           Heinzogeneity, Not application         2.0         2.0%         2.0%         1.00         1.00           Heinzogeneity, Not application         2.0         2.12%         0.05 [-0.32, 0.22]         1.30         0.45         20         1.32%         -0.05 [-0.32, 0.22]         1.30         1.45         1.32%         -0.05 [-0.32, 0.22]         1.33         1.35%         -0.05         1.32%         -0.05         1.31         -0.35%         -0.05         -0.05% <td></td>	
1.3.1 GL in the first Brunc2019 Vijeykumar2020 wang2018 Subtotal (95% CI) Heterogeneity: Tau' Test for overall effe 1.3.2 GI in the thirn Brunc2019 Vijeykumar2020 wang2018	Mean         SD           month         0.12         0.2           1.3         0.8         1.18         0.26           r = 0.01:         Chi² = 3.2         ct: Z = 0.30 (P = 0.4)           dimonth         0.21         0.26         1.7         0.5           1.7         0.5         1.12         0.19         0.19	10 16 36 1, df = 2 777) 10 10	lean SD 0.18 0.16 0.8 0.6 1.13 0.39 (P = 0.20); 0.26 0.24 1.8 0.8 1.12 0.23	10 10 14 34 P = 385 10 10 10 14	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8%	W. Random. 35% Cl -0.06 [-0.22, 0.10] 0.05 [-0.12, 1.12] 0.05 [-0.19, 0.29] -0.05 [-0.16, 0.22] -0.05 [-0.27, 0.17] -0.10 [-0.68, 0.48] 0.00 [-0.15, 0.15]		Bindly of Subgroup         Mean         SD         Total         Weight         N. Random. SD: CI         N           14.1 PPD in the first week         stondsright         20         20         27.%         0.11 [-0.16, 0.40]           Substoci (95%)         20         24         0.49         20         12.7%         0.11 [-0.16, 0.40]           Heinrogeneity. Not applicable         20         29         29         27.%         0.11 [-0.16, 0.40]           Heinrogeneity. Not applicable         20         29         29         27.%         0.11 [-0.16, 0.40]           Test for overall effect 2 = 0.73 (0.76, 0.40)         20         1.27%         0.01 [-0.16, 0.40]         1.40           Substoci (95%)         1.30         0.41         20         1.30         0.45         20         1.2%         -0.05 [-0.32, 0.22]           wang2016         2.44         0.4         16         16         14         1.2%         -0.05 [-0.30, 0.50]         Substoci (95% C0)         36         34         27.5%         0.12 [-4.20, 0.45]         12 [-4.20, 0.45]         1.24         1.24         1.24         1.24         1.24         1.24         1.24         1.24         1.24         1.24         1.24         1.24         1.24         1.24	
1.3.1 GI in the first Brunc2019 Vijaykumar2020 wang2018 Subtotal (95% CI) Heterogeneity: Tau' Test for overall effe 1.3.2 GI in the thirt Brunc2019 Vijaykumar2020 wang2018 zhang2018	Mean         SD           month         0.12         0.2           1.3         0.8         1.18         0.26           * = 0.01; Chi <sup>2</sup> = 3.2         ct; Z = 0.30 (P = 0.30)         0.21         0.26           d month         0.21         0.26         1.7         0.5	10 16 36 1, df = 2 77) 10 10 16 15	lean SD 0.18 0.16 0.8 0.6 1.13 0.39 (P = 0.20): 0.26 0.24 1.8 0.8	10 10 14 34 P = 385 10 10 10 14 15	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 10.5%	W. Random. 35% Cl -0.06 [-0.22, 0.10] 0.50 [-0.12, 1.12] 0.05 [-0.19, 0.29] 0.03 [-0.16, 0.22] -0.05 [-0.27, 0.17] -0.10 [-0.68, 0.48] 0.00 [-0.15, 0.15] -0.21 [-0.41, -0.01]		Bindy cof Subgroup         Mean         SD         Total         Weight         IV. Random, 35%, CI         IV           14.1 PPD in the fits week         stondsrift(95, CI)         1.35         0.46         20         12.7%         0.11 [-0.16, 0.40]           Substati (95% CI)         2.90         2.9         12.7%         0.11 [-0.16, 0.40]           Heitrogeneity, Not applicable         Text for overall effect. Z = 0.73 (P = 0.46)         1.4.2         PO in theit nmonth           14.1 PPD in the first nmonth         stondsrif (95% CI)         2.0         1.43         0.45         20         13.2%         -0.05 (-0.32, 0.22]           wang2016         2.44         0.4         1.43         0.45         20         13.2%         -0.05 (-0.32, 0.22]           Heatrogeneity, Tax <sup>2</sup> 0.44         1.4         1.45         0.26 (p.0.6, 0.50]         36         34         27.5%         0.12 (-0.26, 0.45]         Heatrogeneity, Tax <sup>2</sup> 0.45 (P = 0.45)         Heatrogeneity, Tax <sup>2</sup> 0.45 (P = 0.45) <td></td>	
1.3.1 GI in the first Brunc2019 Vijøykumar2020 wang2018 Subtotal (93% CI) Heterogeneity: Tau' Test for overall effer 1.3.2 GI in the thirr Brunc2019 Vijøykumar2020 wang2018 zhang2018 Subtotal (95% CI)	Mean         SD           month         0.12         0.22           1.3         0.8         1.18         0.26           *= 0.01: CHr = 3.2         Ct. Z = 0.30 (P = 0.4)         0.21         0.26           # month         0.21         0.26         1.7         0.5         1.12         0.19           1.38         0.24         1.38         0.24         1.38         0.24	10 16 36 1, df = 2 77) 10 16 15 51	lean         SD           0.18         0.16           0.8         0.6           1.13         0.39           (P = 0.20);           0.26         0.24           1.8         0.8           1.12         0.23           1.59         0.32	10 10 14 34 P = 385 10 10 10 14 15 49	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 10.5%	W. Random. 35% Cl -0.06 [-0.22, 0.10] 0.05 [-0.12, 1.12] 0.05 [-0.19, 0.29] -0.05 [-0.16, 0.22] -0.05 [-0.27, 0.17] -0.10 [-0.68, 0.48] 0.00 [-0.15, 0.15]		Bindly of Subgroup         Mean         SD         Total         Weight         N. Random, 1953, CI         N           14.1 PPD in the first week         stochnic/1012         1.35         0.46         20         1.27%         0.11 [-0.16, 0.00]           Substati (95% CI)         20         20         12.7%         0.11 [-0.16, 0.40]           First for overall effect Z = 0.73 (P = 0.46)         20         12.7%         0.11 [-0.16, 0.40]           1.42 PPD in the first month shondni(2012         1.33         0.41         20         1.42         0.45         20         1.2.2%         0.05 [-0.32, 0.22]           Substati (95% CI)         2.44         0.4         6         2.16         0.18         4         2.2%         0.20 [-0.56, 0.50]           Substati (95% CI)         2.44         0.4         6         2.16         0.18         4         2.2%         0.20 [-0.66, 0.50]           Heterogeneity, Tark = 0.44, CAP = 3.53, of = 1 (P = 0.06); P = 72%         1.2 [-0.20, 0.40]         1.42 PPD.         1.2 [-0.20, 0.40]           Heterogeneity, Tark = 0.44, CAP = 0.45)         1.43 PPD in the tind month	
1.3.1 GI in the first Brunc2019 Vijaykumar2020 wang2018 Subtotal (95% CI) Heterogeneity: Tau' Test for overall effe 1.3.2 GI in the thirt Brunc2019 Vijaykumar2020 wang2018 zhang2018	Mean         SD           month         0.12         0.2           1.3         0.8         1.18         0.26           *= 0.01; CHP = 3.2         ct; Z = 0.30 (P = 0.01); CHP = 3.2         ct; Z = 0.30 (P = 0.01); CHP = 0.00; CHP	10 10 16 36 1, df = 2 77) 10 10 16 15 51 9, df = 3	lean         SD           0.18         0.16           0.8         0.6           1.13         0.39           (P = 0.20);           0.26         0.24           1.8         0.8           1.12         0.23           1.59         0.32	10 10 14 34 P = 385 10 10 10 14 15 49	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 10.5%	W. Random. 35% Cl -0.06 [-0.22, 0.10] 0.50 [-0.12, 1.12] 0.05 [-0.19, 0.29] 0.03 [-0.16, 0.22] -0.05 [-0.27, 0.17] -0.10 [-0.68, 0.48] 0.00 [-0.15, 0.15] -0.21 [-0.41, -0.01]		Bittory of Subgroup         Mean         SD         Total         Weight         N. Random. 353, CI         N           14.1 PPD in the first week         femory         20         12,7%         0.11 [-0.16, 0.40]         Substati [95, CI)         20         20         12,7%         0.11 [-0.16, 0.40]           Substati [95, CI)         20         20         29         12,7%         0.11 [-0.16, 0.40]           Hemrogeneity, Not applicable         1         20         20         12,7%         0.11 [-0.16, 0.40]           substati [95, CI)         20         20         12,7%         0.11 [-0.16, 0.40]         Substati [95, CI)         20         14,8         0.46         16         16,8         4.44         16         16,0         18         14,27         0.05 [-0.32, 0.22]         Substati [95, CI]         14,3         0.45         20         13,2%         -0.05 [-0.32, 0.23]         Substati [95, CI]         14,4         14,2%         -0.23 [0.06, 0.20]         Substati [95, CI]         14,4         14,2%         -0.23 [0.06, 0.20]         Substati [95, CI]         14,4         14,2%         -0.23 [0.06, 0.20]         Substati [95, CI]         14,1         14,2%         -0.23 [0.06, 0.20]         Substati [95, CI]         14,1         14,2%         -0.23 [0.06, 0.20]         Substati [	
1.3.1 G/i in the first Bruno2019 Vijnytuma2020 vang2018 Subtotal (6% CI) Heterogeneity: Tau Test for overall effe 1.3.2 G/i in the thin Bruno2019 Vijnytuma2020 vang2018 zhang2018 zhang2018 zhang2018 zhang2018 zhang2018	Mean         SD           month         0.12         0.2           1.3         0.8         1.18         0.26           *= 0.01; Chi <sup>2</sup> = 3.2         ct; Z = 0.30 (P = 0.4)         0.21         0.26           1.7         0.5         1.12         0.19         1.38         0.24           *= 0.00; Chi <sup>2</sup> = 0.6         1.7         0.5         1.22         0.19         1.38         0.24           *= 0.00; Chi <sup>2</sup> = 2.6         1.32 (P = 0.4)         1.32 (P = 0.4)         1.32 (P = 0.4)         1.32 (P = 0.4)	10 10 16 36 1, df = 2 77) 10 10 16 15 51 9, df = 3	lean         SD           0.18         0.16           0.8         0.6           1.13         0.39           (P = 0.20);           0.26         0.24           1.8         0.8           1.12         0.23           1.59         0.32	10 10 14 34 P = 385 10 10 10 14 15 49	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 10.5%	W. Random. 35% Cl -0.06 [-0.22, 0.10] 0.50 [-0.12, 1.12] 0.05 [-0.19, 0.29] 0.03 [-0.16, 0.22] -0.05 [-0.27, 0.17] -0.10 [-0.68, 0.48] 0.00 [-0.15, 0.15] -0.21 [-0.41, -0.01]		Study of Subgroup         Mean         SD         Total         Mean         SD         Total         Mean         SD         CI         N           14.1 PPD in the first week         stondski (302         1.3         0.46         20         1.27%         0.11 [-0.16, 0.40]           Substotal (302)         1.3         0.46         20         1.27%         0.11 [-0.16, 0.40]           Test for constal first week         20         20         29         27%         0.11 [-0.16, 0.40]           Test for constal first 2 = 0.73 (# 0.406)         1.43         0.45         20         1.27%         0.11 [-0.16, 0.50]           Substati (302%         1.38         0.41         20         1.43         0.45         20         1.26%         0.05 [-0.32, 0.22]           wang2016         2.44         0.41         16         16         14         14.2%         0.28 [0.06, 0.50]           Substati (302% CD)         3.6         3.6         3.4         27.5%         0.12 [-0.20, 0.45]           Hear count life:         2.70         0.45]         1.42         1.46%         0.10 [-0.10, 0.30]           wang2016         2.28         0.25         16         2.18         0.28         14.46%         0.10 [-0.10, 0.30]	
1.3.1 G/l in the first Brunc2019 Vijaykumar2020 wang2018 Subtotal (1955 CI) Hieterogenety: Tau' Teat for overall effe 1.3.2 G/l in the thirt Brunc2019 Vijaykumar2020 wang2018 subtotal (1955 CI) Hieterogenety: Tau' Teat for overall effe 1.3.3 G/l in the sixtl	Mean         SD           month         0.12         0.2           1.3         0.8         1.18         0.26           1.18         0.26         2         0.30 (P = 0.           d month         0.21         0.26         1.7         0.5           1.12         0.19         0.38         0.24         0.86           1.7         0.5         1.12         0.19         0.26           1.38         0.24         0.26         1.7         0.55           1.22         0.00; CHP = 2.66         CHP = 0.00; CHP = 2.66         CHP = 0.00; CHP = 2.66           ct; Z = 1.32 (P = 0.         h         month         0.21         0.26	10 10 16 36 1, df = 2 777) 10 10 16 15 51 9, df = 3 19)	lean SD 0.18 0.16 0.8 0.6 1.13 0.39 (P = 0.20); 0.26 0.24 1.8 0.8 1.12 0.23 1.59 0.32 (P = 0.44);	10 10 14 34 P = 38% 10 10 10 14 15 49 P = 0%	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 10.5% 36.6%	IV. Random. 355; Cl -0.06 (-0.22, 0.10) 0.05 (-0.12, 1.12) 0.05 (-0.19, 0.29) 0.05 (-0.19, 0.29) 0.05 (-0.27, 0.17) -0.05 (-0.27, 0.17) -0.01 (-0.60, 0.49) -0.21 (-0.41, -0.01) -0.07 (-0.18, 0.03)		Bittory of Subgroup         Mean         SD         Total         Weight         N. Random. 353, CI         N           14.1 PPD in the first week         effondin2012         1.35         0.46         20         12.7%         0.11 [-0.16, 0.40]           Substati (35% CD)         20         20         12.7%         0.11 [-0.16, 0.40]           Heinrogeneity, Not applicable         7         20         12.7%         0.11 [-0.16, 0.40]           Heinrogeneity, Not applicable         7         20         12.7%         0.11 [-0.16, 0.40]           Heinrogeneity, Not applicable         7         20         12.7%         0.11 [-0.16, 0.40]           Havergloitils         2.44         0.4         10         1.43         0.45         20         13.2%         -0.05 [-0.32, 0.22]           Wang2016         2.44         0.4         10         1.43         0.45         20         12.2%         0.26 [0.06, 0.20]           Hearcogeneity, Tat/*         0.04, C1** 3.53, d.4*         10         0.06 [P = 0.06]; P = 275.5%         Test to overall effect. 2* 0.75 (P = 0.45)         1.43         PD in the dim month           Hearcogeneity, Tat/*         0.04, C1** 3.53, d.4*         1.42         1.46.5%         0.10 [-0.10, 0.30]           Jamo2016         2.27	
1.3.1 G in the first Prunce2019 Vijnytumar2020 wang2018 Subbotal (6% C) Heterogeneity: Tai) Test for overall effe 1.3.2 GI in the thirt Brunce2019 Vijnytumar2020 wang2018 Subbotal (6% CI) Heterogeneity: Tai Test for overall effe 1.3.3 GI in the sist Brunce2019	Mean         SD           month         0.12         0.2           1.3         0.8         1.18         0.26           r = 0.01; CHr <sup>2</sup> = 3.2         ct. Z = 0.30 (P = 0.         3         3           d month         0.21         0.26         1.12         0.19           1.12         0.19         1.21         0.26         1.12         0.19           d month         0.21         0.26         1.12         0.19         1.38         0.24           r = 0.00; CHr <sup>2</sup> = 2.6         ct. Z = 1.32 (P = 0.         h month         0.22         0.24         0.22         0.24	10 10 16 36 1, df = 2 777) 10 10 10 15 51 9, df = 3 19) 10	lean SD 0.18 0.16 0.8 0.6 1.13 0.39 (P = 0.20); 0.26 0.24 1.8 0.8 1.12 0.23 1.59 0.32 (P = 0.44); 0.3 0.34	10 10 14 34 P = 385 10 10 14 15 49 P = 0%	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 1.8% 14.8% 10.5% 36.6% 7.5%	N. Random. 355. Cl -0.05 [-0.22, 0.10] 0.05 [-0.12, 1.12] 0.05 [-0.19, 0.29] 0.03 [-0.16, 0.22] -0.05 [-0.27, 0.17] -0.05 [-0.15, 0.15] -0.07 [-0.18, 0.03] -0.07 [-0.18, 0.03] -0.08 [-0.34, 0.18]		Study of Subgroup         Mean         SD         Total         Mean         SD         Total         Mean         SD         CI         N           14.1 PPD in the first week         stondski (302         1.3         0.46         20         1.27%         0.11 [-0.16, 0.40]           Substotal (302)         1.3         0.46         20         1.27%         0.11 [-0.16, 0.40]           Test for constal first week         20         20         29         27%         0.11 [-0.16, 0.40]           Test for constal first 2 = 0.73 (# 0.406)         1.43         0.45         20         1.27%         0.11 [-0.16, 0.50]           Substati (302%         1.38         0.41         20         1.43         0.45         20         1.26%         0.05 [-0.32, 0.22]           wang2016         2.44         0.41         16         16         14         14.2%         0.28 [0.06, 0.50]           Substati (302% CD)         3.6         3.6         3.4         27.5%         0.12 [-0.20, 0.45]           Hear count life:         2.70         0.45]         1.42         1.46%         0.10 [-0.10, 0.30]           wang2016         2.28         0.25         16         2.18         0.28         14.46%         0.10 [-0.10, 0.30]	
1.3.1 G in the first Prunc2019 Vijnykumar2020 wang2018 Subbata (6% c) Test for overall effer 1.3.2 G in the thirn Brunc2019 Vijnykumar2020 wang2018 Subbata (6% c) Heterogeneity: Tau Test for overall effer 1.3.3 G in the sist Prunc2019 wang2018 zhang2018 zhang2018	Mean         SD           month         0.12         0.2           1.3         0.8         1.18         0.26           1.18         0.26         2         0.30 (P = 0.           d month         0.21         0.26         1.7         0.5           1.12         0.19         0.38         0.24         0.86           1.7         0.5         1.12         0.19         0.26           1.38         0.24         0.26         1.7         0.55           1.22         0.00; CHP = 2.66         CHP = 0.00; CHP = 2.66         CHP = 0.00; CHP = 2.66           ct; Z = 1.32 (P = 0.         h         month         0.21         0.26	10 10 16 36 1, df = 2 777) 10 16 15 51 9, df = 3 19) 10 16 15 10 10 10 15 10 10 10 15 10 10 15 10 10 15 10 10 15 10 15 10 10 15 10 15 10 15 10 15 10 10 15 10 10 15 10 10 15 10 10 15 10 10 15 10 10 15 10 10 15 10 10 10 10 10 15 10 10 10 10 10 10 10 10 10 10	lean SD 0.18 0.16 0.8 0.6 1.13 0.39 (P = 0.20); 0.26 0.24 1.8 0.8 1.12 0.23 1.59 0.32 (P = 0.44); 0.3 0.34 0.93 0.21	10 10 14 34 P = 38% 10 10 10 14 15 49 P = 0% 10 14 15	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 14.8% 10.5% 36.6% 7.5% 17.6% 13.2%	N. Random. 35%. Cl.           -0.06 [+0.22, 0.10]           0.05 [+0.22, 0.10]           0.05 [+0.19, 0.29]           0.05 [+0.19, 0.29]           0.05 [+0.27, 0.17]           -0.06 [+0.46, 0.48]           -0.05 [+0.27, 0.17]           -0.01 [+0.46, 0.48]           -0.02 [+0.41, 0.01]           -0.05 [+0.18, 0.01]           -0.06 [+0.34, 0.18]           -0.24 [+0.01, 0.03]		Bitty for Subgroup         Mean         SD         Total         Weight         N. Random, 195, Cl         N           14.1 PPD in the first week         stochold (95, Cl)         20         20         12,7%         0.11 [-0.16, 0.40]           Substaci (95, Cl)         20         20         12,7%         0.11 [-0.16, 0.40]           First for overall effect Z = 0.37 (9° - 0.46)         20         12,7%         0.11 [-0.16, 0.40]           14.1 PPD in the first month stochold (97, Cl)         1.30         0.41         20         12,7%         0.01 [-0.16, 0.40]           14.2 PPD in the first month stochold (97, Cl)         1.30         0.41         20         13,2%         -0.05 [-0.32, 0.22]           wang2016         2.44         0.41         16         14         14,2%         0.28 [0.06, 0.50]           Substaci (19% Cl)         3.6         3.4         27,5%         0.12 [-0.26, 0.45]         Heirogenetity, Tau" = 0.04, Cl" = -3.53, d" + 10 = 0.05; l" = 72%         1.2 [-0.26, 0.45]           14.3 PPD in the third month wang2016         2.270         2.33         0.51         15         12,4%         -0.03 [-0.30]           Text for overall effect Z = 0.70 (P = 0.45)         1.33         0.51         12,2%         -0.03 [-0.30]           Tabeg2016         2.270 <td< td=""><td></td></td<>	
1.3.1 G in the first Brunc2019 Vigiyumra2200 wang2018 Subbota (19% C) Heterogeneity: Tau' Test for overall effe 1.3.2 G in the thirt Brunc2019 Subbota (19% C) Heterogeneity: Tau' Test for overall effe 1.3.3 G in the sixtl Brunc2019 wang2018 schang2018 schang2018 schang2018	a Mean S0 month 0.12 0.2 1.3 0.8 1.18 0.26 ct Z = 0.30 (P = 0. d month 0.21 0.26 1.7 0.5 1.12 0.19 1.38 0.24 e 0.00; CH <sup>2</sup> = 4.0 ct Z = 1.32 (P = 0. h month 0.22 0.24 1.53 0.25	10 10 16 36 1, df = 2 777) 10 16 15 51 9, df = 3 19) 10 16 15 51 9, df = 41	lean         SD           0.18         0.16         0.8         0.6           0.8         0.6         0.3         0.39           (P = 0.20):         0.26         0.24         1.8         0.8           1.12         0.23         1.59         0.32         (P = 0.44);           0.3         0.34         0.93         0.21         1.67         0.22	10 10 34 P = 38% 10 10 14 15 49 P = 0% 10 14 15 39	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 10.5% 36.6% 7.5% 17.6% 33.3%	N. Random. 355. Cl -0.06 [-0.22, 0.10] 0.05 [-0.12, 1.12] 0.05 [-0.12, 1.12] 0.05 [-0.19, 0.23] 0.05 [-0.19, 0.23] 0.05 [-0.27, 0.17] -0.10 [-0.46, 0.48] 0.00 [-0.15, 0.15] -0.07 [-0.16, 0.02] -0.07 [-0.16, 0.02] -0.08 [-0.34, 0.16] 0.12 [-0.01, 0.25]		Bindly of Subgroup         Mean         SD         Total         Mean         SD         Total         Mean         SD         SD         N           14.1 PPD in the first week         stondski (2012)         20         22         22.7%         0.11 [-0.18, 0.40]           Substatial (2015)         20         20         12.7%         0.11 [-0.18, 0.40]           Test to consider black 2.2         0.76         0.41         20.18         20           First to consider black 2.2         0.76         0.41         20.18         20           Stondski (2012)         1.30         0.41         20         1.32%         -0.05 [-0.32, 0.22]           wingd016         2.44         0.4         16         16         1.42         2.29 (0.06, 0.50]           Substatial (90% C1)         1.30         0.41         20         1.32%         -0.05 [-0.32, 0.22]           wingd016         2.40         0.41         16         1.41         14.2%         -0.28 [-0.05, 0.50]           First to consider black 2.2         0.30         1.42         2.75%         0.12 [-0.20, 0.45]           First to consider black 2.2         0.25         16         2.18         2.23         0.25         1.21 [-0.00, 0.20]           I	
1.3.1 G in the first Brunc2019 Vijsykuma2200 wang2018 Slubtotal (#5% CI) Heterogeneity: Tau' Test for overall effe Func2019 Abrunc2019 Justense (#5% CI) Heterogeneity: Tau' Test for overall effe 1.3.3 G in the slutt Brunc2019 Slubtotal (#5% CI) Heterogeneity: Tau' Fang2018 Slubtotal (#5% CI)	a Mean 50 month 0.12 0.2 1.3 0.8 1.18 0.26 = 0.01: Chi <sup>2</sup> = 3.2 ct: Z = 0.30 (P = 0. 1 month 0.21 0.28 1.7 0.5 1.12 0.19 1.38 0.24 *= 0.00; Chi <sup>2</sup> = 2.6 ct: Z = 1.32 (P = 0. h month 0.22 0.24 1.05 0.13 1.53 0.25 *= 0.02; Chi <sup>2</sup> = 6.3	10 10 16 36 1, df = 2 777) 10 10 16 15 51 9, df = 3 19) 10 16 9, df = 3 19) 10 16 9, df = 4 10 10 10 10 10 10 10 10 10 10	lean         SD           0.18         0.16         0.8         0.6           0.8         0.6         0.3         0.39           (P = 0.20):         0.26         0.24         1.8         0.8           1.12         0.23         1.59         0.32         (P = 0.44);           0.3         0.34         0.93         0.21         1.67         0.22	10 10 34 P = 38% 10 10 14 15 49 P = 0% 10 14 15 39	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 10.5% 36.6% 7.5% 17.6% 33.3%	N. Random. 35%. Cl.           -0.06 [+0.22, 0.10]           0.05 [+0.22, 0.10]           0.05 [+0.19, 0.29]           0.05 [+0.19, 0.29]           0.05 [+0.27, 0.17]           -0.06 [+0.46, 0.48]           -0.05 [+0.27, 0.17]           -0.01 [+0.46, 0.48]           -0.02 [+0.41, 0.01]           -0.05 [+0.18, 0.01]           -0.06 [+0.34, 0.18]           -0.24 [+0.01, 0.03]		Bindy of Subgroup         Mean         SD         Total         SD         <	
1.3.1 G in the first Prunc2019 Vignyturna2200 wang2018 Subtotal (8% CI) Histerogeneity: Tau Test for overal effer 1.3.2 G in in the thirr Prunc2019 Vignyturna2200 Subtotal (8% CI) Histerogeneity: Tau Test for overal effer 1.3.3 G in the sixtl Brunc2019 wang2018 scha	a Mean 50 month 0.12 0.2 1.3 0.8 1.18 0.26 = 0.01: Chi <sup>2</sup> = 3.2 ct: Z = 0.30 (P = 0. 1 month 0.21 0.28 1.7 0.5 1.12 0.19 1.38 0.24 *= 0.00; Chi <sup>2</sup> = 2.6 ct: Z = 1.32 (P = 0. h month 0.22 0.24 1.05 0.13 1.53 0.25 *= 0.02; Chi <sup>2</sup> = 6.3	10 10 16 36 1, df = 2 777) 10 10 16 15 51 9, df = 3 19) 10 16 9, df = 3 19) 10 16 9, df = 4 10 10 10 10 10 10 10 10 10 10	lean         SD           0.18         0.16         0.8         0.6           0.8         0.6         0.3         0.39           (P = 0.20):         0.26         0.24         1.8         0.8           1.12         0.23         1.59         0.32         (P = 0.44);           0.3         0.34         0.93         0.21         1.67         0.22	10 10 34 P = 38% 10 10 14 15 49 P = 0% 10 14 15 39	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 10.5% 36.6% 7.5% 17.6% 33.3%	N. Random. 35%. Cl.           -0.06 [+0.22, 0.10]           0.05 [+0.22, 0.10]           0.05 [+0.19, 0.29]           0.05 [+0.19, 0.29]           0.05 [+0.27, 0.17]           -0.06 [+0.46, 0.48]           -0.05 [+0.27, 0.17]           -0.01 [+0.46, 0.48]           -0.02 [+0.41, 0.01]           -0.05 [+0.18, 0.01]           -0.06 [+0.34, 0.18]           -0.24 [+0.01, 0.03]		Study of Subgroup         Mean         SD         Total         Mean         SD         Total         Mean         SD         Total         Mean         SD         CI         Mean         SD         CI         Mean         SD         SD         SD <t< td=""><td></td></t<>	
1.3.1 G in the first Prunce2019 Vijnytumac2020 wang2018 Subbata (1955, CI) Heterogeneity: Tau' Test for overal effe Prunce2019 Vijnytumac2010 Subbata (1955, CI) Heterogeneity: Tau' Test for overal effe 1.3.3 G in the state Subbata (1955, CI) Heterogeneity: Tau' Test for overal effe 1.3.4 G it at one mo	$\label{eq:result} \begin{array}{cccc} a_{-} & {\rm Mean} & {\rm SD} & {\rm month} & \\ 0.12 & 0.2 & \\ 1.3 & 0.8 & \\ 1.18 & 0.26 & \\ e=0.01; (-De^{2}=3.2; (-De^$	10 10 16 36 1, df = 2 10 10 10 10 16 15 51 9, df = 2 9, df = 3 19) 10 16 15 41 9, df = 2 22)	lean         SD           0.18         0.16           0.8         0.6           1.13         0.39           (P = 0.20);           0.26         0.24           1.12         0.23           1.59         0.32           (P = 0.44);         0.3           0.3         0.34           0.93         0.21           1.67         0.22           (P = 0.04);         tment	$\begin{array}{c} 10\\ 10\\ 14\\ 34\\ 7=363\\ 10\\ 10\\ 14\\ 15\\ 49\\ P=056\\ 10\\ 14\\ 15\\ 39\\ P=695\\ \end{array}$	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 10.5% 36.6% 7.5% 17.6% 13.2% 38.3%	N. Random. 355, Cl.           -0.06 (4.22, 0.10)           0.05 (4.12, 1.12)           0.05 (4.12, 0.12)           0.05 (4.12, 0.28)           0.05 (4.12, 0.28)           0.05 (4.12, 0.17)           -0.16 (4.12, 0.17)           -0.05 (4.27, 0.17)           -0.05 (4.27, 0.17)           -0.16 (4.12, 0.17)           -0.07 (4.12, 0.11)           -0.07 (4.12, 0.11)           -0.08 (-0.34, 0.18)           -0.14 (-0.31, 0.03)           -0.32 (-0.34, 0.18)           -0.24 (-0.12, 0.23)		Bindy of Subgroup         Mean         SD         Total         SD         <	
1.3.1 G in the first Brunc2019 Vijnytuma2020 wang2018 Subtotal (1954 CI) Heterogenethy: Tau Test for overal effo Subtotal (1954 CI) Heterogenethy: Tau Test for overal effo Subtotal (1954 CI) Heterogenethy: Tau Test for overal effo 1.3.4 G it at one mou	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	10 10 16 36 1, dl = 2 77) 10 10 10 15 51 51 19) 10 16 15 51 19) 10 16 15 15 15 15 15 15 15 15 15 15	lean         SD           0.18         0.16           0.8         0.6           1.13         0.39           (P = 0.20);           0.26         0.24           1.12         0.23           1.59         0.32           (P = 0.44);         0.3           0.3         0.34           0.93         0.21           1.67         0.22           (P = 0.04);         tment	10 10 14 34 7 = 38% 10 10 14 15 49 P = 0% 14 15 39 P = 0%	14 2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 14.8% 10.5% 36.6% 7.5% 17.6% 38.3% 1.0%	N. Random. 355. Cl -0.06 [-0.22, 0.10] 0.05 [-0.12, 0.10] 0.05 [-0.17, 0.29] 0.05 [-0.19, 0.29] 0.03 [-0.16, 0.22] -0.05 [-0.27, 0.17] -0.01 [-0.46, 0.48] -0.00 [-0.46, 0.48] -0.00 [-0.34, 0.01] -0.07 [-0.18, 0.03] -0.02 [-0.34, 0.18] -0.12 [-0.01, 0.28] -0.4 [-0.30, 0.18] -0.29 [-0.41, 1.19]		Bindy of Subgroup         Mean         SD         Total         Weight         N. Random, 353, Cl         N           14.1 PPD in the first week         stochold (95, Cl)         20         22, 7%         0.11 [-0.16, 0.40]         Substati (95, Cl)         20         29         12, 7%         0.11 [-0.16, 0.40]           Substati (95, Cl)         20         20         12, 7%         0.11 [-0.16, 0.40]         Substati (95, Cl)         20         29         12, 7%         0.11 [-0.16, 0.40]           Herrogeneity, Not applicable         Test to overall effect Z = 0.73 (P = 0.40)         14.3         0.45         20         13.2%         -0.05 [-0.32, 0.22]           Herrogeneity, Cl, Z, J         2.44         0.4         12, 14.3         0.45         20         12, 25, 0.02]         0.22 [-0.06]         12 [-0.28, 0.40]           Herrogeneity, Tax' = 0.44, Cl × = 3.53, of = 1 (P = 0.06); P = 72%         Test to overall effect Z = 0.70 (P = 0.45)         14.46%         0.10 [-0.10, 0.30]           Herrogeneity, Tax' = 0.44, Cl × = 15.35, of = 1 (P = 0.00); P = 72%         Test to overall effect Z = 0.70 (P = 0.45)         12.29         2.35, 0.46 [-0.46]         14.46%         0.10 [-0.10, 0.30]           Herrogeneity, Tax' = 0.24, Cl × 16 (P = 0.000); P = 94%         12.20 (-0.20); P = 94%         12.20 (-0.20); P = 94%         14.46%         0.11 [-0.11 (-0.31]	
1.3.1 G in the first Brunc2019 Vignytuma2200 wang2018 Stubbotal (8% C) Heterogenetity: Tau' Test for overal effe Brunc2019 Vignytuma2200 wang2018 Stubbotal (8% C) Heterogenetity: Tau' Test for overal effe frunc2019 wang2018 Stubbotal (9% C) Stubbotal (9% C)	$\label{eq:result} \begin{array}{cccc} a_{-} & {\rm Mean} & {\rm SD} & {\rm month} & \\ 0.12 & 0.2 & 1.3 & 0.6 & \\ 1.3 & 0.6 & 0.2 & (-D^{2} = 3.2 & ($	10 10 16 36 1, df = 2 10 10 10 10 16 15 51 9, df = 2 9, df = 3 19) 10 16 15 41 9, df = 2 22)	lean         SD           0.18         0.16           0.8         0.6           1.13         0.39           (P = 0.20);           0.26         0.24           1.12         0.23           1.59         0.32           (P = 0.44);         0.3           0.3         0.34           0.93         0.21           1.67         0.22           (P = 0.04);         tment	10 10 14 34 7 = 38% 10 10 14 15 49 P = 0% 14 15 39 P = 0%	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 10.5% 36.6% 7.5% 17.6% 13.2% 38.3%	N. Random. 355, Cl.           -0.06 (4.22, 0.10)           0.05 (4.12, 1.12)           0.05 (4.12, 1.12)           0.05 (4.10, 0.28)           0.05 (4.10, 0.28)           0.05 (4.10, 0.28)           0.00 (4.10, 0.18)           0.00 (4.10, 0.18)           0.00 (4.10, 0.18)           0.00 (4.10, 0.18)           0.00 (4.10, 0.18)           0.00 (4.10, 0.18)           0.00 (4.10, 0.18)           0.14 (4.31, 0.03)           0.05 (4.20, 0.28)           0.00 (4.10, 0.33)           0.00 (4.10, 0.34)			
1.3.1 G is the first Prunc2019 Vijnytuma2020 weng2018 Subtotal (195): G1 Heterogeneth; Tau Test for overal effe therogeneth; Tau Test for overal effe vang2018 subtotal (195): G1 Heterogeneth; Tau Test for overal effe Subtotal (195): G1 Heterogeneth; Tau Subtotal (195): G1 Heterogeneth; Not	a Maar S0. month 0.12 0.2 1.3 0.8 1.18 0.25 *= 0.01; C.0* = 3.2 ± = 0.30; C.0* = 3.2 t. 2 0.00 t. 0.0* = 0.00; C.0* = 2.6 t. 2 0.00 1.35 0.24 *= 0.00; C.0* = 2.6 t. 2 0.00 t. 2 0.00 t	10 10 16 36 1, dt = 2 10 10 10 10 10 15 51 9, dt = 3 19) 10 16 15 51 9, dt = 2 20 19) 10 16 15 51 19) 10 16 15 15 15 15 15 15 16 16 15 15 15 15 15 15 15 16 16 16 15 15 15 15 15 15 15 15 15 15	lean         SD           0.18         0.16           0.8         0.6           1.13         0.39           (P = 0.20);           0.26         0.24           1.12         0.23           1.59         0.32           (P = 0.44);         0.3           0.3         0.34           0.93         0.21           1.67         0.22           (P = 0.04);         tment	10 10 14 34 7 = 38% 10 10 14 15 49 P = 0% 14 15 39 P = 0%	14 2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 14.8% 10.5% 36.6% 7.5% 17.6% 38.3% 1.0%	N. Random. 355. Cl -0.06 [-0.22, 0.10] 0.05 [-0.12, 0.10] 0.05 [-0.17, 0.29] 0.05 [-0.19, 0.29] 0.03 [-0.16, 0.22] -0.05 [-0.27, 0.17] -0.01 [-0.46, 0.48] -0.00 [-0.46, 0.48] -0.00 [-0.34, 0.01] -0.07 [-0.18, 0.03] -0.02 [-0.34, 0.18] -0.12 [-0.01, 0.28] -0.4 [-0.30, 0.18] -0.29 [-0.41, 1.19]		Bioty of Subgroup         Mean         SD         Total         Mean         SD         Total         Mean         SD	
1.3.1 G in the first Prunc2019 Vijnytuma2020 wang2018 Stubtotal (1955, CI) Heterogenethy: Tau Test for overal effe 1.3.2 G in the thir Runc2019 Vijnytuma2020 wang2018 Stubtotal (1955, CI) Heterogenethy: Tau Test for overal effe 1.3.4 G i at one mo wang2018 Stubtotal (1955, CI) Heterogenethy: Tau Test for overal effe Subtotal (1955, CI) Heterogenethy: Tau	a Maar S0. month 0.12 02 1.3 0.8 1.18 0.25 *= 0.01; C.0* = 3.2 ± = 0.30; C.0* = 3.2 t. 2 0.30 t. 2 0.30 t. 2 0.30 1.2 0.10 1.3 0.24 *= 0.00; C.0* = 2.6 c.t Z + 1.32 (P = 0.0) 0.25 0.25 c.t Z = 0.22 (P = 0.0) 0.25 1.45 0.25 1	10 10 16 36 37 77 10 10 16 15 51 9, df = 2 77 10 16 15 51 9, df = 3 19 10 16 15 51 9, df = 2 15 51 19 10 16 15 15 15 15 15 15 15 15 15 15	lean         SD           0.18         0.16           0.8         0.6           1.13         0.39           (P = 0.20);           0.26         0.24           1.12         0.23           1.59         0.32           (P = 0.44);         0.3           0.3         0.34           0.93         0.21           1.67         0.22           (P = 0.04);         tment	$\begin{array}{c} 10\\ 10\\ 14\\ 34\\ 7^{\mu}=38^{3}\\ 10\\ 10\\ 10\\ 14\\ 15\\ 39\\ 10\\ 14\\ 15\\ 39\\ 10\\ 14\\ 15\\ 39\\ 11\\ 41\\ 14\\ 14\\ 14\\ \end{array}$	14.2% 1.0% 8.3% 24.0% 9.5% 1.8% 14.8% 10.5% 38.6% 7.5% 10.2% 38.3%	N. Random. 355, Cl -0.06 (-0.22, 0.10) 0.05 (-0.12, 1.12) 0.05 (-0.12, 0.10) -0.05 (-0.27, 0.17) -0.16 (-0.28) -0.05 (-0.27, 0.17) -0.16 (-0.60, 0.18) -0.00 (-0.41, 0.01) -0.00 (-0.34, 0.18) -0.21 (-0.41, 0.01) -0.00 (-0.34, 0.18) -0.21 (-0.41, 0.01) -0.22 (-0.41, 0.01) -0.22 (-0.41, 0.19) -0.22 (-0.41, 1.19) 0.39 (-0.41, 1.19)		Bindy for Subgroup         Mean         SD         Total         Mean         SD         Total         Mean         SD         SD         C         N           14.1 PPD in the first week         stondinal (95, 01)         20         20         22, 7%         0.11 [-0.16, 0.40]           Substatial (95, 01)         20         20         22, 7%         0.11 [-0.16, 0.40]           Test to constal first x= 0.53 (9* 0.46)         20         12, 7%         0.11 [-0.16, 0.40]           Hetrogenetity, Not applicable         Test to constal first x= 0.53 (9* 0.46)         1.42         9.40         1.2, 5%           Stonding (20, 1)         1.30 0.41         20         1.43, 0.45         20         1.2, 5%         -0.05 [-0.32, 0.22]           wang2016         2.44         0.41         16         16         1.42, 2%         -0.20 [-0.00, 0.03]           wang2016         2.44         0.41         16         1.42, 16%         -0.02 [-0.20, 0.22]           wang2016         2.20         0.25         16         2.14         2.75%         -0.02 [-0.20, 0.22]           wang2016         2.20         0.25         15         1.26, 16%         -0.03 [-0.03, 0.22]         -0.01 [-0.10, 0.30]           substotatial (95% CD)         3.1         <	
1.3.1 G is the first Brunc2019 Vijnytuma2020 wang2018 Stubtotal (195), C J) Test for overal effs Brunc2019 Vijnytuma2020 wang2018 Jang2018	$\label{eq:constraints} \begin{array}{cccc} a & {\rm Mean} & {\rm SO} & {\rm month} \\ 0.12 & 0.2 & 1.3 & 0.8 \\ 1.13 & 0.26 & 2.2 & 0.01 & {\rm Ceh}^2 = 3.2 & 2.2 & 0.01 & {\rm Ceh}^2 = 3.2 & 2.2 & 0.01 & {\rm Ceh}^2 = 3.2 & 2.2 & 0.2 & 0.2 & 1.2 & 0.19 & 1.38 & 0.24 & 4.2 & 0.21 & 0.26 & 1.2 & 0.19 & 1.38 & 0.24 & 4.2 & 0.22 & 0.24 & 1.26 & 0.13 & 1.53 & 0.25 & 1.2 & 0.19 & 0.22 & 0.24 & 1.55 & 1.45 & 0.15 & 1.56 $	10 10 10 10 10 10 10 10 10 10 10 10 10 1	lean         SD           0.16         0.16           0.8         0.6           1.3         0.39           (P = 0.20);           0.26         0.24           1.8         0.8           1.12         0.23           1.59         0.32           (P = 0.44);           0.3         0.34           0.93         0.21           1.67         0.22           (P = 0.04);         1.56	$\begin{array}{c} 10\\ 10\\ 14\\ 34\\ 9\\ 10\\ 10\\ 14\\ 15\\ 49\\ P=0\%\\ 10\\ 14\\ 15\\ 39\\ P=69\%\\ 14\\ 14\\ 14\\ 136\\ \end{array}$	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 36.6% 7.5% 17.8% 10.2% 38.3%	N. Random. 355. Cl -0.06 [-0.22, 0.10] 0.05 [-0.12, 0.10] 0.05 [-0.17, 0.29] 0.05 [-0.19, 0.29] 0.03 [-0.16, 0.22] -0.05 [-0.27, 0.17] -0.01 [-0.46, 0.48] -0.00 [-0.46, 0.48] -0.00 [-0.34, 0.01] -0.07 [-0.18, 0.03] -0.02 [-0.34, 0.18] -0.12 [-0.01, 0.28] -0.4 [-0.30, 0.18] -0.29 [-0.41, 1.19]		Bindy for Subgroup         Mean         5D         Total Mean         SD         Total Mean         SD         Total Mean         N           14.1 PPD in the first week         stochold (SV)         13.5         0.6         20         2.2 %         0.11 [-0.16, 0.03]           Substati (SV)         CO         20         20         12.7 %         0.11 [-0.16, 0.04]           Substati (SV)         CO         20         20         12.7 %         0.11 [-0.16, 0.04]           Heterogeneity, Not applicable         Test for owneil affect Z = 0.7 (P = 0.46)         14.2 %         0.05 [-0.32, 0.22]           Handroxicoliz         1.30         0.41         20         1.42 %         0.02 [0.00, 0.50]           Substati (SV)         36         34         27.5 %         0.12 [-0.20, 0.50]         12.2 %           Heterogeneity, Tau' = 0.04, CPI = 0.35, df = 10 = 0.05; P = 72%         Test for owneil effect Z = 0.70 (P = 0.45)         14.4 6%         0.10 [-0.10, 0.30]           1.4.3 PPD in the third month         stochold 2.2 %         15         3.5 0.5 15         12.5 %         -0.40 [-0.40, 0.30]           1.4.4 PPD in the third month         stochold 2.2 %         15         3.5 0.5 15         12.5 %         -0.40 [-0.40, 0.30]           1.4.4 PPD in the third month         stochold 2.2 %	
1.3.1 G is the first Prunc2019 Vijnytuma2020 wang2018 Stubtotal (49%, CI) Heterogenethy: Tau' Test for overail effe for overail effe Alance overail effe stubtotal (49%, CI) Heterogenethy: Tau' Test for overail effe 1.3.4 G it at one moveragenethy avang2018 stubtotal (49%, CI) Heterogenethy Tau' Test for overail effe 1.3.4 G it at one moveragenethy Stubtotal (5%, CI) Heterogenethy Tau' Heterogenethy Tau' Heterogenethy Tau' Heterogenethy Tau' Heterogenethy: Tau'	a Maar 50. month 0.12 0.2 1.3 0.8 1.8 0.35 2.5 2 − 0.30 (P = 0. 1.8 0.25 1.3 0.25 2.5 2 − 0.30 (P = 0. 1.3 0.25 1.3 0.25 1.2 0.19 1.30 0.24 0.21 0.26 1.7 0.5 1.12 0.19 1.30 0.24 0.21 0.26 1.2 0.19 1.30 0.24 0.21 0.26 1.2 0.19 1.30 0.24 0.22 0.24 1.50 0.25 1.50 0.25 1.50 0.25 1.50 0.25 1.5 0.25 1	10 10 10 36 37 777) 10 10 10 10 10 15 51 15 51 10 16 15 51 19) 10 16 15 51 15 15 15 16 20 20 20 10 10 10 10 10 10 10 10 10 1	lean         SD           0.16         0.16           0.8         0.6           1.3         0.39           (P = 0.20);           0.26         0.24           1.8         0.8           1.12         0.23           1.59         0.32           (P = 0.44);           0.3         0.34           0.93         0.21           1.67         0.22           (P = 0.04);         1.56	$\begin{array}{c} 10\\ 10\\ 14\\ 34\\ 9\\ 10\\ 10\\ 14\\ 15\\ 49\\ P=0\%\\ 10\\ 14\\ 15\\ 39\\ P=69\%\\ 14\\ 14\\ 14\\ 136\\ \end{array}$	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 14.8% 36.6% 7.5% 17.8% 10.2% 38.3%	N. Random. 355, Cl -0.06 (-0.22, 0.10) 0.05 (-0.12, 1.12) 0.05 (-0.12, 0.10) -0.05 (-0.27, 0.17) -0.16 (-0.28) -0.05 (-0.27, 0.17) -0.16 (-0.60, 0.18) -0.00 (-0.41, 0.01) -0.00 (-0.34, 0.18) -0.21 (-0.41, 0.01) -0.00 (-0.34, 0.18) -0.21 (-0.41, 0.01) -0.22 (-0.41, 0.01) -0.22 (-0.41, 0.19) -0.22 (-0.41, 1.19) 0.39 (-0.41, 1.19)	M. Random 92% Cl		
1.3.1 G is the first Brunc2019 Vijnytuma2020 wang2018 Statotata (19%, C) in tatogoniy, T au Test for overal effs Brunc2019 Vijnytuma2020 wang2018 ang2018 st ang2018	a Mean S0 month 0.12 02 1.3 0.8 *= 0.01; Ch <sup>2</sup> = 3.2 ± 6 0.01; Ch <sup>2</sup> = 3.2 ± 6 0.01; Ch <sup>2</sup> = 3.2 ± 7 0.05 1.12 0.19 1.35 0.24 *= 0.00; Ch <sup>2</sup> = 2.6 1.12 0.19 1.35 0.24 *= 0.00; Ch <sup>2</sup> = 2.6 0.15 1.5 *= 0.22 0.24 0.25 0.25 *= 0.22 (P = 0. 1.95 0.15 *= 0.25 (P = 0. 1.95 0.15) *= 0.95 (P = 0. 1.95 0.15) *= 0.95 (P = 0. 1.5 0.15) *= 0.95 (P = 0. *= 0.5) (Ch <sup>2</sup> = 1.5) *= 0.55 (Ch <sup>2</sup> = 1.5) (Ch <sup>2</sup> = 1.5) *= 0.55 (Ch <sup>2</sup> = 1.5) (Ch <sup></sup>	10 10 10 10 36 37 777) 10 10 10 10 10 10 15 51 19 10 16 15 51 19 10 16 15 51 19 10 16 16 16 28 51 19 10 10 10 16 16 16 16 16 16 16 16 16 16	team         SD           0.16         0.16         0.16           0.80         0.6         0.6           0.80         0.6         0.16           1.13         0.39         0.26           0.26         0.26         0.24           1.13         0.33         1.12           0.23         0.34         1.12         0.23           1.19         0.33         0.34         0.35         0.21           0.33         0.34         0.35         0.21         0.89         0.21           0.33         0.34         0.25         0.24         0.23         0.24           0.33         0.34         0.21         0.22         0.23         0.24           0.33         0.34         0.21         0.22         0.22         0.24         0.23         0.24           0.33         0.24         0.22         0.22         0.22         0.22         0.24         0.24         0.24         0.25         0.24         0.25         0.24         0.23         0.24         0.24         0.25         0.24         0.24         0.24         0.24         0.24         0.24         0.24         0.24         0.24 <td< td=""><td>10 10 14 34 9 10 10 10 14 15 49 9 9 0% 10 14 15 39 9 P = 60% 14 14 14 15 39 9 P = 60%</td><td>14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 10.5% 10.5% 10.5% 10.5% 10.5% 10.2% 13.2% 10.0% 10.0%</td><td>N. Random. 355, Cl -0.06 (-0.22, 0.10) 0.05 (-0.12, 1.12) 0.05 (-0.12, 0.10) -0.05 (-0.27, 0.17) -0.16 (-0.28) -0.05 (-0.27, 0.17) -0.16 (-0.60, 0.18) -0.00 (-0.41, 0.01) -0.00 (-0.34, 0.18) -0.21 (-0.41, 0.01) -0.00 (-0.34, 0.18) -0.21 (-0.41, 0.01) -0.22 (-0.41, 0.01) -0.22 (-0.41, 0.19) -0.22 (-0.41, 1.19) 0.39 (-0.41, 1.19)</td><td>M. Random 92% Cl</td><td>Bindly of Subgroup         Mean         SD         Total Mean         SD         Total Mean         SD         Total Mean         N           14.1 PPD in the first week         Stochstal (95% CI)         20         20         12.7%         0.11 [-0.16, 0.40]           Substal (95% CI)         20         20         12.7%         0.11 [-0.16, 0.40]           Substal (95% CI)         20         20         12.7%         0.11 [-0.16, 0.40]           Heirrogeneity, Not applicable         Test for ownell effect Z = 0.70 (* 0.46)         14.2%         0.005 (-0.22, 0.22)           Hubbridgeneity, Tau" = 0.44, 04         16.2 (± 0.16         14         14.2%         0.26 (0.50)           Substal (95% CI)         36         34         27.5%         0.12 (-2.6, 0.45)           Hear ogeneity, Tau" = 0.44, CPI = -3.53, df = 10 = 0.00); P = 7.2%         Test for ownell effect Z = 0.70 (* 0.46)         14.4.6%         0.10 (-0.16, 0.30)           Hear ogeneity, Tau" = 0.44, CPI = 0.35, df = 10 = 0.00); P = 7.2%         Test for ownell effect Z = 0.70 (* 0.46)         14.4.6%         0.10 (-0.16, 0.30)           Hear ogeneity, Tau" = 0.44, CPI = 0.46, P = 7.66, df = 10.40, 0.30 (-10, 0.20, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.36, 0.30, 0.33, 0.37, 3.36, 0.36, 0.30, 0.33, 1.36, 0.37, 3.36, 0.36, 0.30, 0.36, 0.37, 3.36, 0.36, 0.30, 0</td><td></td></td<>	10 10 14 34 9 10 10 10 14 15 49 9 9 0% 10 14 15 39 9 P = 60% 14 14 14 15 39 9 P = 60%	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 10.5% 10.5% 10.5% 10.5% 10.5% 10.2% 13.2% 10.0% 10.0%	N. Random. 355, Cl -0.06 (-0.22, 0.10) 0.05 (-0.12, 1.12) 0.05 (-0.12, 0.10) -0.05 (-0.27, 0.17) -0.16 (-0.28) -0.05 (-0.27, 0.17) -0.16 (-0.60, 0.18) -0.00 (-0.41, 0.01) -0.00 (-0.34, 0.18) -0.21 (-0.41, 0.01) -0.00 (-0.34, 0.18) -0.21 (-0.41, 0.01) -0.22 (-0.41, 0.01) -0.22 (-0.41, 0.19) -0.22 (-0.41, 1.19) 0.39 (-0.41, 1.19)	M. Random 92% Cl	Bindly of Subgroup         Mean         SD         Total Mean         SD         Total Mean         SD         Total Mean         N           14.1 PPD in the first week         Stochstal (95% CI)         20         20         12.7%         0.11 [-0.16, 0.40]           Substal (95% CI)         20         20         12.7%         0.11 [-0.16, 0.40]           Substal (95% CI)         20         20         12.7%         0.11 [-0.16, 0.40]           Heirrogeneity, Not applicable         Test for ownell effect Z = 0.70 (* 0.46)         14.2%         0.005 (-0.22, 0.22)           Hubbridgeneity, Tau" = 0.44, 04         16.2 (± 0.16         14         14.2%         0.26 (0.50)           Substal (95% CI)         36         34         27.5%         0.12 (-2.6, 0.45)           Hear ogeneity, Tau" = 0.44, CPI = -3.53, df = 10 = 0.00); P = 7.2%         Test for ownell effect Z = 0.70 (* 0.46)         14.4.6%         0.10 (-0.16, 0.30)           Hear ogeneity, Tau" = 0.44, CPI = 0.35, df = 10 = 0.00); P = 7.2%         Test for ownell effect Z = 0.70 (* 0.46)         14.4.6%         0.10 (-0.16, 0.30)           Hear ogeneity, Tau" = 0.44, CPI = 0.46, P = 7.66, df = 10.40, 0.30 (-10, 0.20, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.37, 3.36, 0.36, 0.30, 0.33, 0.37, 3.36, 0.36, 0.30, 0.33, 1.36, 0.37, 3.36, 0.36, 0.30, 0.36, 0.37, 3.36, 0.36, 0.30, 0	
1.3.1 Gil In the first Prunc2019 Vijsykumar2020 wang2018 Subtotal (1951-CI) Heterogenethy: Tau' Test for overalt effe Prunc2019 Vijsykumar2020 wang2018 Subtotal (1951-CI) Heterogenethy: Tau' Test for overalt effe subtotal (1951-CI) Heterogenethy: Not Test for overalt effe Heterogenethy: Not Test for overalt effe	a Mean S0 month 0.12 02 1.3 0.8 *= 0.01; Ch <sup>2</sup> = 3.2 ± 6 0.01; Ch <sup>2</sup> = 3.2 ± 6 0.01; Ch <sup>2</sup> = 3.2 ± 7 0.05 1.12 0.19 1.35 0.24 *= 0.00; Ch <sup>2</sup> = 2.6 1.12 0.19 1.35 0.24 *= 0.00; Ch <sup>2</sup> = 2.6 0.15 1.5 *= 0.22 0.24 0.25 0.25 *= 0.22 (P = 0. 1.95 0.15 *= 0.25 (P = 0. 1.95 0.15) *= 0.95 (P = 0. 1.95 0.15) *= 0.95 (P = 0. 1.5 0.15) *= 0.95 (P = 0. *= 0.5) (Ch <sup>2</sup> = 1.5) *= 0.55 (Ch <sup>2</sup> = 1.5) (Ch <sup>2</sup> = 1.5) *= 0.55 (Ch <sup>2</sup> = 1.5) (Ch <sup></sup>	10 10 10 10 36 37 777) 10 10 10 10 10 10 15 51 19 10 16 15 51 19 10 16 15 51 19 10 16 16 16 28 51 19 10 10 10 16 16 16 16 16 16 16 16 16 16	team         SD           0.16         0.16         0.16           0.80         0.6         0.6           0.80         0.6         0.16           1.13         0.39         0.26           0.26         0.26         0.24           1.13         0.33         1.12           0.23         0.34         1.12         0.23           1.19         0.33         0.34         0.35         0.21           0.33         0.34         0.35         0.21         0.89         0.21           0.33         0.34         0.25         0.24         0.23         0.24           0.33         0.34         0.21         0.22         0.23         0.24           0.33         0.34         0.21         0.22         0.22         0.24         0.23         0.24           0.33         0.24         0.22         0.22         0.22         0.22         0.24         0.24         0.24         0.25         0.24         0.25         0.24         0.23         0.24         0.24         0.25         0.24         0.24         0.24         0.24         0.24         0.24         0.24         0.24         0.24 <td< td=""><td>10 10 14 34 9 10 10 10 14 15 49 9 9 0% 10 14 15 39 9 P = 60% 14 14 14 15 39 9 P = 60%</td><td>14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 10.5% 10.5% 10.5% 10.5% 10.5% 10.2% 13.2% 10.0% 10.0%</td><td>N. Random. 355, Cl -0.06 (-0.22, 0.10) 0.05 (-0.12, 1.12) 0.05 (-0.12, 0.10) -0.05 (-0.27, 0.17) -0.16 (-0.28) -0.05 (-0.27, 0.17) -0.16 (-0.60, 0.18) -0.00 (-0.41, 0.01) -0.00 (-0.34, 0.18) -0.21 (-0.41, 0.01) -0.00 (-0.34, 0.18) -0.21 (-0.41, 0.01) -0.22 (-0.41, 0.01) -0.22 (-0.41, 0.19) -0.22 (-0.41, 1.19) 0.39 (-0.41, 1.19)</td><td>M. Random 92% Cl</td><td>Bindly of Subgroup         Mean         SD         Total         Mean         SD         Total         Mean         SD         SD         N           14.1 PPD in the first week         Stochold (95: 01)         20         20         12.7%         0.11 [-0.16, 0.40]           Substatia [95: 01)         20         20         12.7%         0.11 [-0.16, 0.40]           Test to constant lends: Z = 0.73 (# 0.40)         20         12.7%         0.11 [-0.16, 0.40]           Hetrogenetity, Not applicable         Test to constant lends: Z = 0.73 (# 0.40)         14.8         0.40           Stochotd (95: 02)         3.6         3.4         27.8%         0.005 [-0.32, 0.22]           wang2016         2.44         0.4         16.216         0.18         14.12%         0.20 [0.00, 0.03]           Substatia [95% C0]         3.6         3.4         27.9%         0.12 [-0.30, 0.45]         Test to constal lends: Z = 0.70 (P = 0.00); P = 72%           Test to constal lends: Z = 0.70 (P = 0.00); P = 0.00); P = 72%         Test to constal lends: Z = 0.70 (P = 0.00); P = 92.45%         Test to constal lends: Z = 0.70 (P = 0.00); P = 92.45%         Test to constal lends: Z = 0.70 (P = 0.00); P = 94.5%           Test to constal lends: Z = 0.70 (P = 0.00); P = 0.000; P = 92.5%         Test to constal lends: Z = 0.70 (P = 0.000); P = 0.000; P = 0.00</td><td></td></td<>	10 10 14 34 9 10 10 10 14 15 49 9 9 0% 10 14 15 39 9 P = 60% 14 14 14 15 39 9 P = 60%	14.2% 1.6% 8.3% 24.0% 9.5% 1.8% 10.5% 10.5% 10.5% 10.5% 10.5% 10.2% 13.2% 10.0% 10.0%	N. Random. 355, Cl -0.06 (-0.22, 0.10) 0.05 (-0.12, 1.12) 0.05 (-0.12, 0.10) -0.05 (-0.27, 0.17) -0.16 (-0.28) -0.05 (-0.27, 0.17) -0.16 (-0.60, 0.18) -0.00 (-0.41, 0.01) -0.00 (-0.34, 0.18) -0.21 (-0.41, 0.01) -0.00 (-0.34, 0.18) -0.21 (-0.41, 0.01) -0.22 (-0.41, 0.01) -0.22 (-0.41, 0.19) -0.22 (-0.41, 1.19) 0.39 (-0.41, 1.19)	M. Random 92% Cl	Bindly of Subgroup         Mean         SD         Total         Mean         SD         Total         Mean         SD         SD         N           14.1 PPD in the first week         Stochold (95: 01)         20         20         12.7%         0.11 [-0.16, 0.40]           Substatia [95: 01)         20         20         12.7%         0.11 [-0.16, 0.40]           Test to constant lends: Z = 0.73 (# 0.40)         20         12.7%         0.11 [-0.16, 0.40]           Hetrogenetity, Not applicable         Test to constant lends: Z = 0.73 (# 0.40)         14.8         0.40           Stochotd (95: 02)         3.6         3.4         27.8%         0.005 [-0.32, 0.22]           wang2016         2.44         0.4         16.216         0.18         14.12%         0.20 [0.00, 0.03]           Substatia [95% C0]         3.6         3.4         27.9%         0.12 [-0.30, 0.45]         Test to constal lends: Z = 0.70 (P = 0.00); P = 72%           Test to constal lends: Z = 0.70 (P = 0.00); P = 0.00); P = 72%         Test to constal lends: Z = 0.70 (P = 0.00); P = 92.45%         Test to constal lends: Z = 0.70 (P = 0.00); P = 92.45%         Test to constal lends: Z = 0.70 (P = 0.00); P = 94.5%           Test to constal lends: Z = 0.70 (P = 0.00); P = 0.000; P = 92.5%         Test to constal lends: Z = 0.70 (P = 0.000); P = 0.000; P = 0.00	

Fig 2 Forest plots for clinical periodontal parameters. a. plaque index; b. bleeding on probing index; c. gingival index; d. periodontal pocket depth.

interventions in both studies. Only Sfondrini et al<sup>31</sup> claimed that the periodontists who were responsible for periodontalparameter evaluation were blinded for previous scores; Bruno et al<sup>3</sup> did not mention the measure for blinding evaluators. No missing outcome data or bias of selective report was found among the included RCTs.

Among n-RCTs, three<sup>21,41,43</sup> were considered to have moderate bias, while the other three<sup>10,36,40</sup> were assessed as possessing serious bias according to the ROBINS-I assessment tool (Table 4). The most severely affected domains were the selection of participants and missing data. Bias in deviations from intended interventions as well as blindness in outcomes measurements could not be ignored. In terms of reporting bias and classification of interventions, all involved studies were considered as having a low risk of bias due to sufficient details provided, and reported and specific classification of interventions.

#### **Results of Individual Studies**

The results and conclusions of individual studies are described in Supplement 1, in which we provide an overview of the difference in clinical periodontal parameters between fixed labial and lingual orthodontic therapy.

# **Results of Meta-Analyses and Additional Analyses**

Three studies<sup>10,21,36</sup> were not included in the meta-analyses due to using different periodontal assessment indices with high clinical heterogeneity. Specifically, Lombardo et al<sup>21</sup> reported the presence of PI and gingival bleeding index (GBI) with continuous statistics, the study of Gujar et al<sup>10</sup> did not report which periodontal indices applied. Tapia-Rivera et al<sup>36</sup> reported the presence of visible PI, modified GI (dichotomised as adequate and mild gingivitis), and the presence of BOP as dichotomised results.<sup>36</sup> As the odds ratio (OR) was only reported in one study<sup>36</sup> and these dichotomised results without raw data could not be pooled with continuous results, this study was not included in the current meta-analysis. Therefore, only 5 studies were involved in the quantitative analyses.

Three investigations<sup>3,40,41</sup> reported plaque index according to the Loe-Silness method,<sup>32</sup> comprising 70 participants who were pooled statistically. In terms of tooth position de-

#### **Table 5** Summary of findings table according to the GRADE approach

Dationt or popu	lation, nationto reaciving fixed labial or ling	ual arthodoptic tracts	mont						
Patient or population: patients receiving fixed labial or lingual orthodontic treatment Intervention: Settings: Periodontal status between fixed labial and lingual orthodontic treatment									
Outcomes	Relative effect* (95% CI)	No. of participants (studies)	Quality of evidence (GRADE)	Comments					
	Corresponding risk Periodontal status between fixed labial and lingual orthodontic treatment								
Plaque index	The mean plaque index in the intervention groups was 0.14 lower (0.27 to 0.02 lower)	220 (3 studies)	$\bigoplus_{\text{very low}^{1,2}} \bigoplus_{1,2}$	The plaque index was lower in the fixed lingual orthodontic therapy compared with the fixed labial orthodontic treatment.					
Periodontal pocket depth	The mean periodontal pocket depth in the intervention groups was 0.06 higher (0.16 lower to 0.27 higher)	260 (3 studies)	$\bigoplus \bigoplus \bigoplus \bigoplus \bigoplus \bigoplus$ very low <sup>1,2,3,4</sup>	No statistically significant difference was found in periodontal pocket depth between the fixed labial and lingual orthodontic treatment.					
Bleeding on probing index	The mean bleeding on probing index in the intervention groups was 0.11 higher (0.03 lower to 0.25 higher)	180 (2 studies)	$\bigoplus_{\text{very low}^{1,2,3}} \bigoplus_{\text{very low}^{1,2,3}}$	No statistically significant difference was found in bleeding on probing index between the fixed labial and lingual orthodontic treatment.					
Gingival index									

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.

<sup>1</sup> Non-randomised clinical trials invovled.

<sup>2</sup> The sample size of the meta-analysis was limited to draw a precise estimate of effect.

<sup>3</sup> There was at least one study that was assessed as having high or serious risk of bias.

<sup>4</sup> There was high heterogeneity across the involved studies.

tection, Wang et al<sup>41</sup> chose Ramfjord teeth (tooth numbers 16, 21, 24, 36, 41, and 44) for tooth detection, while Bruno et al<sup>3</sup> assessed all teeth and Vijavkumar et al<sup>40</sup> only evaluated the PI of mandibular anterior teeth. However, only Bruno et al<sup>3</sup> described examining four sites (vestibular, lingual, mesial, and distal surfaces) for PI, and the other two did not report specific sites per tooth chosen for measurement. Low statistical heterogeneity was observed across the related studies ( $X^2 = 11.25$ ;  $I^2 = 29\%$ ). PI was statistically significantly lower in patients receiving the fixed lingual orthodontic treatment compared to those undergoing traditional fixed labial orthodontic treatment (MD = 0.14; 95% CI, 0.02 to 0.27), while subgroup analyses yielded no statistically significant difference at each follow-up timepoint (Fig 2a). With regard to BOP, two studies<sup>41,43</sup> comprising 60 participants were included in the quantitative synthesis. Both studies evaluated BOP according to the Mazza method,<sup>24</sup> yet the tooth positions detected were different and no specific sites per tooth were reported. As opposed to Wang et al,<sup>41</sup> who chose Ramfjord teeth to assess BOP, Zhang et al<sup>43</sup> only assessed the BOP of four teeth (tooth numbers 16, 11, 31, and 46), but

neither reported specific sites chosen per tooth for measurement. We found no statistically significant difference in BOP between the labial and lingual group (MD = -0.11; 95% Cl, -0.25 to 0.03), with moderate heterogeneity ( $X^2 = 14.23$ ;  $I^2 = 65\%$ ). Similarly, no statistically significant difference was found in terms of BOP at each follow-up timepoint according to subgroup analyses (Fig 2b). Regarding GI, four studies<sup>3,40,41,43</sup> using the Loe-Silness method<sup>20</sup> were deemed eligible for meta-analysis. Wang et al<sup>41</sup> and Bruno et al<sup>3</sup> took the GI at four sites per tooth, while Vijaykumar et al<sup>40</sup> and Zhang et al<sup>43</sup> did not report the specific site in detail. The meta-analysis in terms of GI involved 100 participants and these 100 participants were the sum of the participants in the four experiments described above. No statistically significant difference in GI between patients undergoing fixed lingual orthodontic therapy and those with traditional labial orthodontic appliances (MD = -0.02; 95% CI, -0.11 to 0.06;  $X^2 = 14.69$ ;  $I^2 = 32\%$ ) was observed. Our results of subgroup analyses according to follow-up duration were consistent with the former results<sup>3,41</sup> (Fig 2c). Three studies<sup>31,41,43</sup> which reported PPD results from 80 participants were deemed eligible for quantitative analysis. Zhang et al<sup>43</sup> reported the mean value of six sites around the measured teeth (tooth numbers 16, 11, 31 and 46), while the other two<sup>31,41</sup> did not report tooth positions or specific sites at which PPD was measured. Similar PPDs were observed using the two systems, but considerable heterogeneity was found (MD = -0.06; 95% CI, -0.27 to 0.16; X<sup>2</sup> = 33.17; I<sup>2</sup> = 79%). Subgroup analyses showed no statistically significant difference between the two groups at each follow-up period (Fig 2d). Further sensitivity analysis or publication bias assessment were ultimately not conducted, due to the paucity of existing studies contributing to the quantitative synthesis.

# **Risk of Bias Across the Studies**

The overall quality of evidence assessed by the GRADE approach is exhibited in Table 5. As recommended in the Cochrane Handbook for Systematic Reviews of Interventions Version 6.2, the overall quality of evidence from non-randomised clinical trials began with low quality. In general, the outcome of PI, BOP, and PPD was determined as having very low quality due to the involvement of non-randomised clinical trials, imprecision, and a high risk of bias within the studies. The quality pertaining to the GI was evaluated as low due to involving non-randomised clinical trials.

# DISCUSSION

Maintaining an acceptable level of oral hygiene was of great importance during the course of orthodontic treatment to avoid any adverse effects related to periodontal health. The current review systematically examined all available evidence on clinical periodontal parameters during the course of fixed labial and lingual orthodontic treatment. Based on the 8 included clinical investigations with 223 patients, the current review found no statistically significant differences in periodontal parameters between fixed labial and lingual orthodontic systems. However, the overall quality was very low to low, indicating that further RCTs with larger sample size and standardised outcome measures are needed.

In the past, it was generally acknowledged that patients with fixed lingual orthodontic appliances should pay more attention to oral hygiene, as it was more difficult to conduct daily oral hygiene procedures blindly from the lingual side, also given the wider brackets and reduced inter-bracket distance.14,15 However, our results found a lower plaque index in the lingual group; this could partly be due to the lingual surface of the teeth being closer to the tongue and the open salivary duct. It has been reported that the flushing effect of saliva might interfere with bacterial adherence and biofilm formation on the lingual side.<sup>7,9,21</sup> Moreover, the activity of the tongue also contributes to the mechanical cleaning of dental plaque on the lingual side of the teeth.<sup>39</sup> These two self-cleaning mechanisms might help reduce plaque accumulation on the lingual surface of the teeth.<sup>39</sup> However, this finding should be interpreted with great caution, due to the very low quality of evidence. No statistically significant difference was found concerning the BOP, GI, and PPD between patients receiving the fixed labial and those who received lingual orthodontic treatment. The results of BOP, GI, and PPD were inconsistent with the results of PI according to our study. A possible explanation might be that the follow-up duration of most of the included investigations was too short to detect biological alterations in the periodontal tissues.<sup>38</sup> Therefore, further investigations with longer follow-ups are warranted to confirm the results of the current study. In addition, since gingivitis is a risk factor for attachment loss and clinical attachment loss (CAL), which has been highlighted as one of the characteristics of periodontitis,<sup>37</sup> future studies focusing on differences in attachment loss between patients receiving fixed labial vs lingual orthodontic treatment should be conducted.

Clinically, treatment outcome and safety in terms of periodontal health were not the sole considerations when patients chose the appliance type and therapeutic strategy for orthodontic treatment.<sup>25</sup> The cost was also an important influencing factor, as lingual orthodontics is currently considerably more expensive due to its manufacturing technology. Therefore, patients should be instructed about treatment effects, potential adverse effects, and costs when choosing orthodontic appliances to ensure that patient is well-informed about treatment planning.

# **Strengths and Limitations**

Previous reviews focused on the self-reported difficulty in conducting daily oral hygiene measures.<sup>1,27</sup> The patient-report outcome could not reflect the real clinical periodontal status. The present study was the first systematic review to consider all available evidence using objective clinical periodontal parameters to compare periodontal health between patients receiving fixed labial and lingual orthodontic treatment. Our study thus constitutes a comprehensive and systematic evaluation of the efficacy of contemporary fixed orthodontic appliances in helping maintain periodontal health during treatment.

However, there are some limitations to the current systematic review and meta-analysis, the main one being the inclusion of non-randomised clinical trials.<sup>2</sup> Although randomised controlled clinical trials are considered the gold standard for clinical trials, performing random assignment requires extra financial support. The fact that the selection of orthodontic appliances is influenced by the patient's socioeconomic status and their aesthetic requirements must also be considered.17 Similarly, allocation concealment is also difficult to perform due to the nature and appearance of the orthodontic appliances. Thus, non-randomised clinical trials were also considered acceptable. Moreover, in the current study, the limited number of investigations included prohibited robust assessments of heterogeneity, subgroup analyses for many confounding factors, and publication bias assessment.<sup>28</sup> Additionally, the sample size of the included studies was small, which leads to the retrieved results lacking adequate precision. Also the short follow-up duration in most included studies precludes the assessment of the long-term influence of the orthodontic appliance on periodontal health, since such biological alterations take time.

Therefore, more studies comparing the clinical periodontal parameters between the fixed labial and lingual orthodontic technique with a larger sample size, standardised methodology, and longer follow-up period are recommended to confirm the conclusions of the present review.

# CONCLUSIONS

This review found that the periodontal status in patients undergoing fixed labial and lingual orthodontic treatment was similar. From the clinical point of view, the fixed lingual orthodontic appliance is comparable to the fixed labial orthodontic appliance with regard to the clinical periodontal parameters. However, more studies with high quality, larger sample size, and longer follow-up are necessary in order to validate our findings.

# ACKNOWLEDGEMENTS

The National Natural Science Foundation of China [81771030, 82071080] funded this study and paid for article processing charges.

# REFERENCES

- Ata-Ali F, Ata-Ali J, Ferrer-Molina M, Cobo T, De Carlos F, Cobo J. Adverse effects of lingual and buccal orthodontic techniques: A systematic review and meta-analysis. Am J Orthod Dentofac Orthoped 2016;149:820–829.
- Bondemark L, Ruf S. Randomized controlled trial: the gold standard or an unobtainable fallacy? Eur J Orthod 2015;37:457–461.
- Bruno G, De Stefani A, Pillan M, Balasso P, Mazzoleni S, Gracco A, et al. Vestibular and lingual orthodontics: experimental study on plaque and blood indexes. Minerva Stomatolog 2019;68:285–290.
- Cohen J. A coefficient of agreement for nominal scales. Edu Psycholog Measure 1960;20:37–46.
- Curtis MA, Diaz PI, Van Dyke TE. The role of the microbiota in periodontal disease. Periodontol 2000 2020;83:14–25.
- Darveau RP, Curtis MA. Oral biofilms revisited: A novel host tissue of bacteriological origin. Periodontol 2000 2021;86:8–13.
- Demling A, Demling C, Schwestka-Polly R, Stiesch M, Heuer W. Short-term influence of lingual orthodontic therapy on microbial parameters and periodontal status: a preliminary study. Angle Orthod 2010;80:480–484.
- Fritz U, Diedrich P, Wiechmann D. Lingual technique patients' characteristics, motivation and acceptance. Interpretation of a retrospective survey. J Orofac Orthop 2002;63:227–233.
- Gross A, Barnes GP, Lyon TC. Effects of tongue brushing on tongue coating and dental plaque scores. J Dent Res 1975;54:1236.
- Gujar AN, Baeshen HA, Alhazmi A, Ghoussoub MS, Raj AT, Bhandi S, et al. Comparison of biochemical markers of bone metabolism between conventional labial and lingual fixed orthodontic appliances. Niger J Clin Pract 2020;23:568–573.
- Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011;64:380–382.
- 12. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series, ed 1. Hoboken: John Wiley, 2008.
- 13. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–1558.
- Hohoff A, Fillion D, Stamm T, Goder G, Sauerland C, Ehmer U. Oral comfort, function and hygiene in patients with lingual brackets. A prospective longitudinal study. J Orofac Orthop 2003;64:359–371.
- Hohoff A, Stamm T, Kühne N, Wiechmann D, Haufe S, Lippold C, et al. Effects of a mechanical interdental cleaning device on oral hygiene in patients with lingual brackets. Angle Orthod 2003;73:579–587.
- Jakubovics NS, Goodman SD, Mashburn-Warren L, Stafford GP, Cieplik F. The dental plaque biofilm matrix. Periodontol 2000 2021;86:32–56.

- Jiang Q, Li J, Mei L, Du J, Levrini L, Abbate GM, et al. Periodontal health during orthodontic treatment with clear aligners and fixed appliances: A meta-analysis. JADA (1939) 2018;149:712–720.e712.
- Joseph S, Curtis MA. Microbial transitions from health to disease. Periodontol 2000 2021;86:201–209.
- Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics 2018;74:785–794.
- Loe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odont Scand 1963;21:533–551.
- Lombardo L, Ortan YO, Gorgun O, Panza C, Scuzzo G, Siciliani G. Changes in the oral environment after placement of lingual and labial orthodontic appliances. Prog Orthod 2013;14:28–28.
- Long H, Zhou Y, Pyakurel U, Liao L, Jian F, Xue J, et al. Comparison of adverse effects between lingual and labial orthodontic treatment. Angle Orthod 2013;83:1066–1073.
- Lossdörfer S, Schwestka-Polly R, Wiechmann D. Control of lower incisor inclination with a completely customized lingual appliance for dentoalveolar compensation of class III malocclusion. J Orofac Orthop 2013;74:381–396.
- Mazza JE, Newman MG, Sims TN. Clinical and antimicrobial effect of stannous fluoride on periodontitis. J Clin Periodontol 1981;8:203–212.
- Oikonomou E, Foros P, Tagkli A, Rahiotis C, Eliades T, Koletsi D. Impact of aligners and fixed appliances on oral health during orthodontic treatment: a systematic review and meta-analysis. Oral Health Prev Dent 2021;19: 659–672.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
- Papageorgiou SN, Gölz L, Jäger A, Eliades T, Bourauel C. Lingual vs. labial fixed orthodontic appliances: systematic review and meta-analysis of treatment effects. Eur J Oral Sci 2016;124:105–118.
- Papageorgiou SN, Papadelli AA, Eliades T. Effect of orthodontic treatment on periodontal clinical attachment: a systematic review and meta-analysis. Eur J Orthod 2018;40:176–194.
- Ren Y, Jongsma MA, Mei L, van der Mei HC, Busscher HJ. Orthodontic treatment with fixed appliances and biofilm formation-a potential public health threat? Clin Oral Investig 2014;18:1711–1718.
- Sedghi L, DiMassa V, Harrington A, Lynch SV, Kapila YL. The oral microbiome: Role of key organisms and complex networks in oral health and disease. Periodontol 2000 2021;87:107–131.
- Sfondrini MF, Debiaggi M, Zara F, Brerra R, Comelli M, Bianchi M, et al. Influence of lingual bracket position on microbial and periodontal parameters in vivo. J Appl Oral Sci 2012;20:357–361.
- Silness J, Loe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odont Scand 1964;22:121–135.
- Spineli LM, Pandis N. Fixed-effect versus random-effects model in meta-regression analysis. Am J Orthod Dentofac Orthop 2020;158:770–772.
- Sterne JAC HM, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, et al. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ 2016;355:i4919.
- Sterne JAC SJ, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366: I4898.
- Tapia-Rivera JG, Cotrim-Ferreira A, Borelli-Neto L, Prieto MG, Ferreira-Santos RI. Periodontal health in patients under conventional and lingual orthodontic therapies. Revista de Odontologia da UNESP 2015;44:251–256.
- Tonetti MS, Sanz M. Implementation of the new classification of periodontal diseases: Decision-making algorithms for clinical practice and education. J Clin Periodontol 2019;46:398–405.
- Tsichlaki A, Chin SY, Pandis N, Fleming PS. How long does treatment with fixed orthodontic appliances last? A systematic review. Am J Orthod Dentofac Orthop 2016;149:308–318.
- van der Veen MH, Attin R, Schwestka-Polly R, Wiechmann D. Caries outcomes after orthodontic treatment with fixed appliances: do lingual brackets make a difference? Eur J Oral Sci 2010;118:298–303.
- Vijaykumar V, R VK, Archana D, Sekar A, Deepak A, Umapathy V, et al. Comparison of the periodontal status of patients undergoing labial and lingual orthodontic therapy. Cureus 2020;12:e6818.
- Wang X, Zheng H, Jia P. Comparison of dynamic changes in periodontal health between patients receiving lingual and labial orthodontics. J Biomater Tissue Engineer 2018;8:1370–1374.
- Yener SB, Özsoy Ö P. Quantitative analysis of biofilm formation on labial and lingual bracket surfaces. Angle Orthod 2020;90:100–108.
- Zhang SaTW. Comparative study on the effects of lingual and labial orthodontics on periodontal tissues. J Shanxi Med Univ 2018;49:1246–1250.

Author, year	Outcome assessed	Measure of outcome/method of outcome assessment	Results	Conclusions
Tapia-Rivera et al, 2015	<ol> <li>The presence of visible plaque</li> <li>Bleeding on probing</li> <li>Modified gingival index</li> <li>Simplified oral hygiene index</li> </ol>	OR of following outcomes: 1. Presence of plaque 2. Bleeding on probing 3. Modified gingival index 4. Simplified oral hygiene index Method: 1. Buccal surface of 11 and 31, lingual surface of 11 and 31, buccal surface of 16 and 26 2. Buccal and lingual surfaces of maxillary posterior teeth, buccal and lingual surfaces of mandibular posterior teeth 3. Buccal surface of 11 and 31, lingual surface of 11 and 31, buccal surface of 16 and 26 4. Buccal surface of 11 and 31, lingual surface of 11 and 31.	<ol> <li>Higher risk of presence of plaque on the buccal surface in the labial group, but higher risk of presence of plaque on the lingual surface in the lingual group.</li> <li>Higher risk of bleeding on probing on the buccal surface in the labial group, but risk of bleeding on probing on the lingual surface in the lingual group.</li> <li>Higher risk of modified gingival index on the buccal surface in the labial group, but risk of modified gingival index on the lingual surface in the lingual group.</li> <li>No statistically significant difference in simplified oral hygiene index between the labial and lingual groups.</li> </ol>	The clinical periodontal health conditions may be considered acceptable for patients using both conventional and lingual brackets
Bruno et al, 2019	1. Plaque index 2.Gingival index	<ul> <li>Mean ± SD of following outcomes:</li> <li>1. Plaque index at the vestibular, lingual, mesial and distal surface.</li> <li>2. Gingival index at the vestibular, lingual, mesial and distal surface.</li> <li>Measurements of all teeth</li> </ul>	<ol> <li>No statistically significant difference in plaque index between the labial and lingual groups.</li> <li>No statistically significant difference in gingival index between the labial and lingual groups.</li> </ol>	There is no statistically significan difference between the vestibular and lingual appliances.
Gujar et al, 2020	<ol> <li>Plaque index</li> <li>Gingival index</li> <li>Bleeding on probing index</li> </ol>	Not reported	<ol> <li>No statistically significant difference in plaque index between the labial and lingual group.</li> <li>No statistically significant difference in gingival index between the labial and lingual groups.</li> <li>No statistically significant difference in bleeding on probing index between the labial and lingual groups.</li> </ol>	No statistically significant difference with regard to plaque index, gingival index, and bleeding on probing index between the labial and lingual groups.
Lombardo et al, 2013	<ol> <li>Decayed, missing, and filled teeth index</li> <li>Plaque index</li> <li>Gingival bleeding index</li> <li>Salivary flow rate</li> <li>Salivary buffer capacity and pH</li> <li>Streptococcus mutans count</li> <li>Lactobacillus count</li> </ol>	<ol> <li>Mean ± SD in decayed, missing, and filled teeth index</li> <li>Plaque index were expressed as percentages of the total number of tooth surfaces examined</li> <li>Gingival bleeding index were expressed as percentages of the total number of tooth surfaces examined</li> <li>Mean ± SD in salivary flow rate</li> <li>Mean ± SD in salivary buffer capacity and pH.</li> <li>Defined the counts into low, moderate or high level according to the colony counts. Described as percentage of low, moderate or high level.</li> <li>At six sites around each tooth</li> <li>At six sites around each tooth</li> <li>Salivary collections for salivary flow rate, salivary buffering capacity and pH, Streptococcus mutans count, and Lactobacillus count.</li> </ol>	<ol> <li>No statistically significant difference was found in plaque index between the fixed labial and lingual groups.</li> <li>No statistically significant difference was found in gingival bleeding index between the fixed labial and lingual groups.</li> <li>No statistically significant difference was found in salivary flow rate between the fixed labial and lingual groups.</li> <li>No statistically significant difference was found in salivary flow rate between the fixed labial and lingual groups.</li> <li>No statistically significant difference was found in salivary buffer capacity and pH between the fixed labial and lingual groups.</li> <li>No comparison in Streptococcus mutans count and Lactobacillus count between the fixed labial and lingual groups.</li> </ol>	Higher plaque deposited, more gingival inflammation and more S. mutans counts in the lingual group. No statistically significant difference was found in lactobacillus counts, the salivary flow rate, and saliva buffer capacity.
Sfondrini et al, 2012	<ol> <li>Colony-forming units</li> <li>Periodontal pocket depth</li> <li>Bleeding on probing index</li> </ol>	<ol> <li>The total count of microorganisms was determined on countable plates.</li> <li>The pocket depths were measured at the buccal, lingual, mesial and distal sides of the tooth and rounded off to the nearest 0.5 mm.</li> <li>BOP was recorded (0: absent; 1: present) 24 s after determination of PPD.</li> <li>Measurement of the canine and the first premolar of each quadrant</li> </ol>	<ol> <li>No statistically significant differences were found between buccal and lingual brackets in terms of colony-forming units.</li> <li>No statistically significant differences were found between buccal and lingual brackets in terms of periodontal pocket depth.</li> <li>No statistically significant differences were found between buccal and lingual brackets in terms of bleeding on probing index.</li> </ol>	Bracket position does not have a statistically significant impact on bacterial load or periodontal parameters.
Vijaykuma et al, 2020	<ol> <li>Plaque index</li> <li>Calculus index</li> <li>Gingival index</li> </ol>	<ol> <li>Mean ± SD in plaque index.</li> <li>Mean ± SD in calculus index.</li> <li>Mean ± SD in gingival index.</li> <li>Method not reported.</li> </ol>	<ol> <li>In the third month, all three indices were statistically significant for both labial and lingual therapy.</li> <li>The lingual appliance showed more plaque and calculus accumulation.</li> </ol>	The lingual surface of patients undergoing lingual orthodontic treatment exhibited more plaque and calculus deposition, thereby worsening the periodontal status.
Wang et al, 2018	<ol> <li>Gingival index</li> <li>Plaque index</li> <li>Sulcular bleeding index</li> <li>Periodontal depth</li> </ol>	<ol> <li>Gingival tissues were divided into four areas for scoring: mesial, distal, buccal, and lingual area. Mean ± SD in gingival index.</li> <li>Mean ± SD in plaque index.</li> <li>Mean ± SD in sulcular bleeding index.</li> <li>Mean ± SD in periodontal depth.</li> <li>A, 24, 36, 41 and 44 were chosen for tooth detection</li> </ol>	<ol> <li>No statistical significance was observed throughout the changing pattern.</li> <li>No statistical significance was noted in the periodontal index between two groups after 1-, 3- and 6-month treatment</li> </ol>	It is more difficult to maintain the oral hygiene after lingual orthodontics compared with labia orthodontics, whereas the status of periodontal health does not statistically significantly differ after lingual and labial orthodontic treatment.
Zhang et al, 2018	<ol> <li>Gingival index</li> <li>Bleeding on probing index</li> <li>Periodontal pocket depth</li> </ol>	<ol> <li>Mean ± SD in gingival index.</li> <li>Mean ± SD in bleeding on probing index.</li> <li>Six sites around the teeth were detected. Mean ± SD in periodontal pocket depth. Measurements of 16, 11, 31, and 46</li> </ol>	<ol> <li>The PD, GI, and BI values were higher in both groups at the 3rd and 6th month of correction compared with those before correction.</li> <li>The PD, GI, and BI were statistically significantly higher in the lingual group than in the labial group at the 3rd and 6th month of correction.</li> <li>The grupher of heateries other than</li> </ol>	Compared with labial fixed orthodontic treatment, the effect of lingual fixed orthodontic treatment affects the cleanliness of periodontal tissues, and the maintenance of oral health should be a priority when lingual fixed

correction. 3. The number of bacteria other than Actinobacillus actinomycetemcomitans in the lingual group was higher than that in the labial group at months 3 and 6 of correction.

#### Supplement 1 Reported outcomes of the included studies

Mean: mean difference; SD: standard deviation.

be a priority when lingual fixed orthodontic treatment is performed.